AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.
Page references to Supplement 1 (October 2001), Supplement 2 (October 2001), Supplement 3 (October 2001), Supplement 4 (October 2001), Supplement 5 (November 2001), and Supplement 6 (December 2001) are preceded, respectively, by S1:, S2:, S3:, S4:, S5:, and S6:.

Abbate, M., 196
Abe, K., 736
Abichandani, R., 803
Abraham, M., S5:51
Adams, N.D., 4:E18
Adhikarla, R., 1408
Afuso, H., 64
Agar, J., 1217
Agarwal, R., 853, 1245
Agodoa, L., 744
Akai, Y., S1:182
Akiba, T., S1:50, 147, 212
Akizawa, T., S1:147
Akl, A. I., 1277
Akmal, M., S1:195
Aksoy, H., 6:E39
Alanore, A.L.B., 302
Aldigier, J-C., 510
Allegri, L., 6:E35
Allon, M., 975
Alloway, R.R., 132
Alm, P., 1026
Alperson, B.L., 523
Ambrosius, W.T., 792
Amdahl, M., S5:57
Amir, G., 395
Anastasio, P., S1:38
Andany, M. A., 1065
Anderson, S., 1145
Andrés, A., 640
Andress, D.L., S5:41
Andreucci, M., 18
Antonello, A., 165
Aoike, I., 4:E19
Apsner, R., 979
Arlt, V. M., 5:E26
Arrigo, G., 240
Asnaghi, V., 465
Astor, B.C., 494
Atkins, R.C., 761
Au, T.C., 256
Avorn, J., 1178
Avram, M. M., 1334, 1351, 1358
Axelson, O., 1001

Bagby, S.P., 104
Bahner, U., 296
Baigent, C., 537
Bailey, E.M., 4:E20
Baillod, R.A., 631
Baksh, F.K., 354
Ball, E., 6:E32
Balletta, M.M., 18
Ballmer, P. E., 1199
Balogun, R.A., 4:E18
Baptista, M. A. S. F., 1108
Barone, J. A., 1284
Barr, M.L., 580
Barrett, B., 1398
Bartlett, C., 109
Bartosik, L.P., 728
Basile, D.P., 887
Batiuk, T.D., 792
Batlle, D., 646, S5:51
Batuman, V., 6:E33
Baylis, C., 1292
Bazzi, C., 240
Becker, B., 1245
Bedinger, M.R., 813
Beisiegel, U., 619
Bellinghieri, G., S1:115, 118
Beltrame, A., 240
Belz, M.M., 770
Bendayan, M., 1298
Bene, B., 565
Benito, A., 640
Bergman, S., 529
Berland, Y., 310
Betriu, A., 965
Bettencourt, P., 502
Bianchi, G., 1158
Bieler, C. A., 5:E26
Biolo, G., S1:63
Birkenhäger, W. H., 1158
Birn, H., 196
Bits, H., 395
Blake, P. G., 1119
Bleyer, A.J., 699
Block, G., 1251
Bloembergen, W. E., 992
Boletta, A., 1421
Bonfante, L., 165
Bont, G., 42
Bonventre, J.V., 430
Bostom, A.G., 85, S1:91
Boullay, F., 296
Bragonzi, A., 1421
Braillon, P., 366
Brand, E., 1158
Brand, R., 1229
Brandt, M.L., 553
Bräsen, J.H., 619
Brener, Z., 5:E28
Brenner, B. M., 1365
Brewer, E.D., 553, 754
Brezina, M., 91
Brophy, P.D., 173
Brown, A.J., S5:1, 3
Brown, C. D., 1414
Brown, W.W., S1:8
Browne, B.J., 169
Buchmayer, H., 77, 979
Bunchman, T.E., 173
Buoncristiani, U., 371
Burdmann, E. A., 1108
Burgess, E., 1398
Burns, A., 631
Burrows, P., 42
But, P. P. H., 5:E26
Buzio, C., 6:E35
Buzza, M., 1217

Caldeira, C., 1108
Calò, L., 165
Canton, A.D., 286
Cantor, T.L., S1:172
Carlisle, E, 1398
Carnevali, L., 6:E35
Caruana, R.J., 547
Cattellani, W., 6:E35
Cattran, D.C., 728
Caulfield, P., 42
Cerqueira-Gomes, M., 502
Chagnac, A., 1129
Chak, W.L., 127, 390
Chan, H. H.-L., 6:E38
Chan, J.C.-N., 9
Chan, K.W., 256
Chan, L., S6:2
Chan, T.M., 317, 1055, 6:E38
Chan, Y.-W., 1307
Chan, Y.H., 127, 390
Chandler, G., 988
Chang, Y., 658
Charytan, C., 426
Chattopadhyay, J., 1358
Chau, K.F., 127, 390
Chawla, L. S., 1311
Cheek, D., 744
Che-Fai Hui, A., 400

Chegini, S., 1311
Chen, C.-H., 1074
Chen, C-L., 876
Chen, H.-C., 1096
Chen, T.-W., 941
Cheng, C.-H., 1074
Cheung, A.K., 575
Cheung, C.Y., 127, 390
Chiba, S., 736
Chiou, Y-S., 876
Chishti, A.S., 754
Choi, K.S., 127, 390
Choi, P.C.L., 588
Choi, Y.J., S1:204
Chou, K-J., 876
Chow, K.M., 9, 1:E3, 400, 588
Choy, B. Y., 1055
Christensen, E.I., 196
Christensen, N.J., 664, 679, 696
Chu, W.S., S1:200
Chuang, L.-M., 1185
Chuang, L.-Y., 1096
Chung, H-M., 876, 4:E17
Chung, S.H., S1:200
Ciao, G., 371
Cicconi, B., 371
Cimmino, A., S1:85
Cirillo, M., 664, 675, 691, 696, S1:38
Clunk, J.M., 349
Cochat, P., 366
Cockerill, F.R., 4:E22
Cohen, D., S6:10
Cohen, L., 884, 5:E28
Coleman, M. Jr., 896
Colina, F., 640
Collins, A.J., S1:26
Colucci, P., 1009
Colville, D., 1217
Comper, W.D., 144
Comte, L., 510
Coresh, J., 494
Correia, F., 502
Cortese, M., 1421
Cosma, M., 36
Costeas, C., 1284
Cosyns, J.-P., 5:E26
Cotrufo, M., S1:38
Courtoy, P. J., 1421
Couser, W. G., 1385
Cox-Reijven, P.L., 832
Craver, L., 965
Crook, E.D., 652
Culleton, B., 1122
Curtis, J.J., 349
Cury, P. M., 1108

Da'as, N., 395
D'Agati, V.D., 437, 658, 1135
Dagher, H., 1217
Dahlberg, B., 1001
D'Amico, G., 240
Daneker, B., 839
D'Angelo, A., 165
Danielson, B., 1065
Darmon, D., 395
Daugirdas, J.T., S4:11
Davar, J., 631
Davenport, A., 631
David, L., 366
Davis, J. L., 1245
Davis, P.A., 165
De Bustillo, E.M., 640
Deen, P. M., 1421
DeGroof, R., 1414
De Jong, P. E., 1381
Del Giudice, R., 465
Delosreyes, G., 518
Deng, J-F., 4:E17
De Santo, L.S., S1:38
De Santo, N.G., 664, 675, 691, 696, S1:38, 85
De Santo, R.M., S1:38, 115
Desmond, R.A., 529
Devuyst, O., 1421
De Water, R., 331
De Zeeuw, D., 1381
Dhingra, R. K., 935, 1240
Diaz-Buxo, J.A., 225
Dickenmann, M., 3:E13
Dieplinger, H., 619
Di Leo, R., S1:118
Dittrich, E., 118
Djurdjev, O., 1398
Dodd, S., 6:E32
Dohi, Y., S1:182
Dominguez-Gil, B., 640
Donaldson, C., 1122
Donarski, N., 619
Donnelly, S., 415
Dozio, B., 3:E11
Droz, D., 2:E7
Drüeke, T.B., S1:143
Drummer, C., 664, 668, 679, 684, 691, 696
Duman, N., 6:E39
Dussol, B., 310
Dworkin, L.D., 85

Earnest, M.P., 770
Edvardsson, V., 473
Egidi, M.F., 132
Eisele, G., 42
Elinder, C.-G., 1001
Elsamaloty, H., 5:E29
Emala, C.W., 610
Emeis, J. J., 1376
Emoto, M., S1:186
Emovon, O.E., 169
Enab, Y. M., 1277
Endo, Y., 1082
Engels, K., 1292
Eppel, G.A., 144
Epstein, M., 1145
Erbay, B., 6:E39
Ertürk, S., 6:E34, 6:E39
Esposito, R., 18
Ethier, J., 1398
Ettenger, R.B., S2:22
Eustace, J.A., 494

Faber, M.D., 4:E20
Fabrizi, F., 919, 1009
Fagard, R., 1158
Fagugli, R.M., 371
Fakhouri, F., 302, 2:E7
Falk, A., 560
Fan, S. L. S., 6:E32
Fang, H-C., 876
Fassett, R., 1217
Feber, J., 366
Feehally, J., 881
Fein, P., 1351
Feix, A., 956
Ferguson, R.M., 580
Fernández, E., 965
Ferreira, A., 502
Fibla, J., 965
Fick-Brosnahan, G.M., 770
Finazzi, S., 1009
Fineder, L., 619
Fink, N.E., 494
Finkel, K.W., 1:E2, 2:E5, 3:E10, 4:E16, 5:E25, 6:E31
Finkelstein, S.D., 354
Fischereder, M., 1061
Flanagan, K. H., 975
Fleisch, M., 867
Fleury, R.N., 26
Födinger, M., 77, 956
Fogo, A., 1:E1, 2:E4, 3:E9, 4:E15, 5:E24, 1329, 6:E30
Forero, F.V., S5:20
Forrest, K., 6:E36
Frankenfield, D.L., 813
Freedman, B.I., 547
Friedlander, G., 652
Friedman, E.A., 518, 1414
Fritsche-Polanz, R., 956
Fuβhöller, A., 867
Fujii, K-i., S1:129
Fujinaga, Y., S1:134
Fujisawa, M., 1191
Fujita, T., 1082
Fukagawa, M., S1:152, 172, 175
Fukiyama, K., 64, 1235
Furuichi, K., 1169
Furuta, T., 736
Fushimi, K., S1:212

Gaber, A.O., 132
Gabow, P.A., 770
Gafter, U., 1129
Galbraith, C., S6:10

Galletti, P., S1:85
Gardner, J.J., 173
Garini, G., 6:E35
Garlick, P. J., 1199
Garrett, L.E., 547
Gassensmith, C.M., 792
Gaston, R., S6:2, 25
Gatson, R. S., S6:2, 25
Gauer, S., 153
Gejyo, F., 70, S1:156
Ger, J., 4:E17
Germain, M.J., 884
Germino, G. G., 1421
Gewirtz, A., 6:E36
Ghelardi, R., 465
Giachelli, C.M., S1:34
Gieseler, F., 1026
Gillerot, G., 5:E26
Gingras, D., 1298
Gitnick, G., 91
Gitomer, J.J., 1:E2, 2:E5, 3:E10, 4:E16, 5:E25, 6:E31
Gloor, J.M., 4:E22, S2:3
Glynn, R. J., 1178
Godwin, M., 42
Goebel, J., 6:E36
Goldberg, S. J., 5:E28
Goldstein, S.L., 553
González, E.A., S5:34, 57, 1430
Goral, S., 896
Goto, S., 4:E19
Goux, N., 565
Govani, M., S2:16
Grabensee, B., 867
Gradzki, R., 1240
Greene, T., 744
Greer, J.W., 813
Greive, K.A., 144
Grewal, H.P., 132
Grimm, E.M., S2:22
Guarnieri, G., S1:63
Guéry, B., 302
Guh, J.-H., 1096
Gupta, A., 488
Guzman, N. J., 1311

Ha, H., S1:200, 204
Haag-Weber, M., 118
Haas, M., 205
Haba, T., S1:168, 175
Hachisuka, T., S1:168
Haizuka, H., S1:54
Halbert, R.J., 580
Handelman, G., 1408
Haneda, M., S1:178
Haramaki, N., 1191
Haramaki, R., 1191
Harchowal, J., 988
Hardy, M.A., 658
Harezlak, J., 792
Hariharan, A., S6:1, 2, 44
Hariharan, S., S6:1, 2, 44
Hartikainen, J., 1208
Hartner, A., 153
Hashimoto, K., 1038
Hassell, D. R. M., 948
Hathaway, D.K., 132
Hayslett, J.P., 893
Hébert, M.-J., 1271
Heer, M., 664, 668, 675, 684, 691, 696
Hegbrant, J., 377
Heidenheim, A.P., 565
Heidland, A., 296, 785, S1:100
Heinz, G., 77
Helderman, J.H., 580, 1439
Hellström, L., 1001
Hemming, A.W., 31
Henning, R. H., 1381
Hernández, D., 1065
Herrmann, S.-M., 1158
Herzog, C., S1:26
Hibi, Y., S1:168
Higa, S., 64
Hilgers, K.F., 153
Hirakata, E., S1:129
Hirakata, H., S1:129
Hirasawa, Y., S1:107
Hirsch, H.H., 3:E13
Hirth, R.A., 824
Hisada, Y., 1169
Hisano, S., 1082
Hjaltadottir, G., 473
Ho, C.T.K., 256
Hoenich, N. A., 1408
Hogan, M.C., 4:E22
Holley, J.L., 847
Holt, C.O., 169
Holt, S.G., 631
Holthouse, D., 2:E6
Homel, P., 1408
Horigome, I., 736
Horiuchi, S., 1016
Hörl, W.H., 77, 118, S1:20, 956, 979
Horn, R., 896
Hosokawa, T., 1038
Hotta, N., 265
Hotta, O., 736
Houtsmuller, A.B., 331
Hovind, P., 1376
Howarad, A.D., S6:51
Howard, A. D., S6:51
Howard, R.J., 31
Hozayen, O., 847
Hricik, D.E., 409, 580, S2:1, 11
Hsu, S. I.-H., 1045
Huang, J.-S., 1096
Huang, J-J., 98
Huang, T.-P., 941
Huang, X.R., 761
Hughes, R.L., 770
Humphreys, M. H., 1251
Hung, S.-C., 941
Hung, S.-H., 941
Hung, W.-C., 1096
Hunsicker, L.G., S1:191

Ibayashi, S., S1:129
Ifudu, O., 518
Ikäheimo, R., 1208
Ikedo, H., 1191
Imanishi, Y., S1:139, 165
Imoberdorf, R., 1199
Inaba, M., S1:4, 30, 139, 186, 208
Inagaki, H., S1:168, 175
Ingrosso, D., S1:85
Inoshita, S., S1:50
Inoue, T., 64
Iorio, L., S1:38
Iseki, K., 64, S1:212, 1235
Ishimura, E., S1:4, 30, 139, 186, 208
Ito, H., 1038
Ito, I., 265
Ivanova, L. V., 1026
Iwano, M., S1:182
Iwasaki, Y., S1:172, 175
Izumotani, T., S1:208

Jaber, B. L., 1105
Jackson, E., 6:E36
Jadoul, M., 5:E26
Järup, L., 1001
Jerums, G., 144
Jiang, Y.-D., 1185
Jindal, K., 1398
Jinde, K., 761
Jofre, R., 443
Johnson, A., 339
Johnson, A.M., 770
Jomori, T., 265
Jones, C., 1217
Jones, H.J., 537
Jones, S.G., 597
Jones, S.H., 179
Jono, S., S1:34, 47

Kaehny, W.D., 770
Kalantar-Zadeh, K., 1251, 1343
Kale, A.S., 553, 754
Kanai, H., S1:129
Kanauchi, M., S1:182
Kaplan, A.A., 4:E18, 426
Kapoor, R., 488
Kars, S.M., 858
Kasayama, S., S1:161
Kasiske, B. L., 1065
Katayama, A., S1:168, 175
Kaufman, A.M., 5:E28
Kaufman, J.M., 371
Kausz, A.T., 803
Kaysen, G. A., 1385
Kazama, J.J., S1:152, 156, 172, 175
Kazmi, W.H., 803

Keane, W.F., 1372, S1:8
Kendall, M.J., 537
Kenderes, B., 547
Kendrick, E., S6:36
Keven, K., 6:E34, E39
Khan, M.A., 529
Khan, S., 803
Khurshid, H., 4:E18
Kientsch-Engel, R., 785
Kiessling, S., 6:E36
Kikkawa, R., S1:178
Kikuchi, K., S1:212
Kim, J.K., S1:200
Kim, M., S1:139, 208
Kim, S-T., S1:220
Kimmel, P.L., 839
Kimura, H., 70
King, J.A.C., 169
King, K., 847
Kingdon, E.J., 631
Kirchner, H., 1264
Kissane, J., 274
Kist-Van Holthe, J. E., 1229
Klag, M.J., 49, 494
Kleger, G.-R., 1199
Kleinman, Y., 395
Kletzmayr, J., 77, 956
Knebelmann, B., 2:E7
Kobayashi, K.-I., 1169
Kojima, Y., S1:161
Kok, D.J., 331, 1229
Komarnicki, M., S1:111
Komers, R., 1145
Konoma, T., S1:54
Kooman, J.P., 832, 948
Kopolovic, J., 395
Kopple, J.D., S1:68, 1251, 1343
Koya, D., S1:178
Koyama, H., S1:47
Koytak, E. S., 6:E34
Krämer, B. K., 1061
Kramer, H.J., 664, 675, 696
Krane, V., S1:14
Kraut, J.A., 703
Kreft, B., 1264
Krisher, J., 547
Krüger, S., 1264
Kubo, K., S1:212
Kudelka, T.L., 173
Kühler, E., 1229
Kumeda, Y., S1:139
Kurioka, Y., S1:139
Kurokawa, K., 761, S1:147
Kurosawa, T., S1:172
Kurtz, I., 703
Kurtzman, N. A., 1113, 1316
Kutlay, S., 6:E34
Kuwabara, Y., S1:129
Kuwahara, M., S1:50
Kwan, T.H., 256
Kwok Wai Lam, P., 588
Laakso, M., 1208
Lacson, E. Jr., 225
Lai, C.-K., 1307
Lai, F.M., 588
Lai, F.M-M., 1:E3, 317
Lai, K.N., 6:E38, 186, 317, 1055
Lai, Y.-H., 1096
Laitinen, T., 1208
Lajoie, G., 728
Laliberty, P., 85
Lam, C.-W., 1307
Lam, C.W.K., 317
Lampainen, E., 1208
Lan, H.Y., 761
Land, W., 1061
Landgren, C., 565
Landray, M.J., 537
Landwehr, D.M., 57
Lang, T., 979
Langone, A. J., 1329, 1439
LaPointe, M.S., 646
Larson, T.S., S2:3
Lau, C.S., 256
Lau, L.-K., 1307
Laverman, G. D., 1381
Laxdal, T., 473
Leavey, S. F., 935
Lee, E., 6:E37
Lee, H.B., S1:200, 204
Lee, H.T., 610
Lee, P-T., 876, 4E:17
Lee, W.-C., 1074
Leenen, P.J.M., 331
Lemaire, M., 2:E7
Le Meur, Y., 510
Lerma, E., S5:51
Leroux-Robert, C., 510
Lesavre, P., 2:E7
Leung, J., 127
Leung, J.C.K., 317
Leung, S.H., 127
Leunissen, K.M.L., 832, 948
Levin, A., 1398
Levin, N. W., 1408
Levin, R., 1178
Levy, R.I., 3:E12
Lewis, E.J., S1:191
Lewis, J., 744
Lewis, K. E., 6:E32
Lewis, R., 1245
Leypoldt, J.K., 575
Li, C.S., 127, 390
Li, F. K., 1055
Li, F.-K., 6:E38
Li, P.K.-T., 9, 1:E3, 400, 588
Li, S., S1:26
Lian, J.-D., 1074
Libetta, C., 286
Lilaj, T., 118
Lim, V.S., S1:80
Lin, C-Y., 349
Lin, J., 437
Lindberg, J.S., S5:57
Lindsay, R.M., 565
Llach, F., S5:1, 20, 45, 57
Lo, A., 132
Lo, W. K., 1055
Lo Forti, B., S1:115
Lohse, P., 1061
López-Gómez, J.M., 443
Lordnejad, R.M., 867
Lorgeot, V., 510
Lu, M-Y., 279
Luft, F. C., 1437
Lui, S. L., 1055
Lui, S.F., 588
Lumiaho, A., 1208
Lundberg, M., 1001
Lunghi, G., 1009

Ma, J.Z., S1:26
Macdougall, I. C., 988
Macdougall, I.C., 649
Madore, F., 1271
Maehara, A., 1235
Maekawa, K., S1:139, 208
Maestroni, A., 465
Makino, H., S1:134
Malhotra, K., S5:57
Mallamace, A., S1:115
Manganelli, P., 6:E35
Manns, B., 1122
Marco, M. P., 965
Marcus, R.J., 57
Markowitz, G.S., 437, 658, 1135
Martin, D.R., 274
Martin, K.J., S5:34, 57, 1430
Martin, P., 91, 919
Martins, L., 502
Marumo, F., S1:50
Maruyama, H., S1:156
Masakane, I., S1:212
Masse, M., 1271
Massry, S.G., S1:58
Matas, A.J., 580
Mathis, A. S., 1284
Matsumoto, J., S1:54
Matsumoto, N., S1:186
Matsuo, S., 265
Matsushima, K., 1169
Matsushita, M., 1082
Maxvold, N.J., 173
Mayr, M., 3:E13
Mazák, I., 785
McBryde, K.D., 173
McClean, J., 1065
McClellan, W., 1045
McClellan, W.M., 547, 813
McCormmick, D., S5:51
McDougal, G., 853
McGlynn, F.J., 537
McLaughlin, K., 1122

McNurlan, M. A., 1199
Meleg-Smith, S., 6:E33
Mendelssohn, D., 36, 1398
Meng, J., 1016
Meregalli, G., 465
Messana, J. M., 935, 1240
Metzger, T., S1:14
Middleton, J., 744
Miettinen, R., 1208
Mihatsch, M.J., 3:E13
Milam, R., 813
Miller, F., 6:E37
Miller, S.B., 274
Milliner, D.S., 4:E22
Minga, T. E., 975
Minutolo, R., 18
Mitch, W. E., 1318, 1337
Mittman, N., 1351, 1358
Miyauchi, A., S1:161
Miyazaki, M., 736
Miyazaki, R., 70
Miyazaki, S., 4:E19, S1:107
Mizuno, M., 265
Modi, K.S., 5:E29
Moe, S.M., 792
Mok, C.C., 256
Molony, D.A., 1:E2, 2:E5, 3:E10, 4:E16, 5:E25, 6:E31
Monaco, L., 1421
Morales, J.M., 640
Morange, S., 310
Mori, K., S1:34, S1:47, S1:134
Morii, H., S1:1, 4, 34, 139, 208
Moriki, T., 1038
Morita, T., 4:E19, S1:107
Morris, C.D., 104
Morrisey, K., 597
Morton, R., 42
Moschella, C., 1105
Moscow, J., 6:E36
Moss, A.H., 847
Motoyama, K., S1:186
Mottes, T.A., 173
Mukaida, N., 1169
Mukoyama, M., S1:134
Müller-Steinhardt, M., 1264
Muñoz, M.A., 640
Murata, G.H., 862
Muratani, H., 1235
Murphy, B., 1115
Murphy, C.L., 792
Musolino, R., S1:118
Myint, M. M., 1351

Nafziger, D.A., 4:E20
Nagae, T., S1:134
Nagai, R., 1016
Nagasue, K., S1:139
Nagy, J., 785
Nakai, S., S1:212
Nakamura, S., S1:107
Nakane, H., S1:129
Nakanishi, S., S1:172
Nakanishi, T., S1:95
Nakao, K., S1:134
Nakashima, Y., S1:54
Nakayama, E.E., 26
Navis, G., 1381
Nedelkov, D., 481
Ne'eman, Z., 395
Nelson, R.W., 481
Neves, W. S., 1108
Ni, Y-H., 279
Nickeleit, V., 3:E13
Nicolaides, M., 437
Niemitukia, L., 1208
Nigg, A.L., 331
Nikolic-Paterson, D.J., 761, 1321
Nishikawa, K., 265
Nishiya, K., 1038
Nishizawa, Y., S1:1, 4, 30, 34, 47, 139 147, 186, 208
Nissenson, A. R., 1390
Niwa, T., S1:107
Noël, L-H., 2:E7
Noordermeer, C., 331
Nord, E. P., 6:E37
Norris, K.C., 523
Norsk, P., 664, 668, 679, 684, 696
Nuchtern, J.G., 553
Numano, M., S1:168

Obrador, G.T., 803
O'Connor, D., 744
Oddoze, C., 310
Odselius, R., 377
Ohi, H., 384
Ohta, T., S1:139
Ojo, A., 744
Okada, S., S1:161
Okado, T., S1:50
Okuda, S., 1191
Okuno, S., S1:139, 208
Okuno, Y., S1:47
Olafsson, I., 473
Olsson, L-F., 377
Onuchic, L. F., 1421
Oo, K. K., 1358
Osama, S., 2:E8
Otoshi, T., S1:139, 208
Owda, A., 2:E8
Owen, W.F., Jr., 57, 182, 426, 1178
Ozaki, H., S1:182
Özcan, M., 6:E34
Ozono, K., S1:161
Öztas, E., 6:E39

Paganini, E.P., 426
Pagano, A., 1009
Palmisano, J., 4:E18
Palsson, R., 473
Pandey, C.M., 488
Pansute, A.M., 249
Papagiannopoulos, M., 77
Papapoulos, S. E., 1229
Parving, H.-H., 1376
Pasini, P., 371
Pasticci, F., 371
Patton, P.R., 31
Pennell, D., 631
Perazella, M.A., 4:E23, S4:26
Pereira, B.J.G., 803
Perna, A., S1:38
Perna, A.F., S1:85
Perneger, T.V., 49
Perniok, A., 867
Perrone, R.D., 777
Perschl, A., 77
Persson, B., 1001
Pescovitz, M.D., S2:16
Pestana, M., 502
Peterson, R.A., 839
Petrini, C., 240
Pham, P-A.T., 3:E14
Pham, P-C.T., 3:E14
Pham, P-T.T., 3:E14
Phillips, A.O., 597
Phillips, R., 744
Pietrzak, I., S1:111
Pinto, S.W.L., 249
Pirsch, J.D., 580
Pisani, A., 18
Pisano, L., 240
Plouin, P-F., 302
Plum, J., 867
Podestá, F., 465
Poldelski, V., 339
Pollastro, M.R., S1:38
Polliack, A., 395
Ponticelli, C., 919
Porst, M., 153
Port, F. K., 1240
Porth, J., 5:E27
Portugal, H., 310
Powe, N.R., 494
Powell, H., 1217
Praloran, V., 510
Price, S. R., 1337
Pröls, F., 153
Proppe, D., 1026
Pusey, C. D., 1324
Puttinger, H., 118

Qian, F., 1421
Quaschning, T., S1:14
Que, I., 1229
Qui, C., 1292
Quintaliani, G., 371

Rabb, H., 1065
Raftery, M. J., 6:E32
Rajwani, I., 518

Ramirez, S. P. B., 1045
Rampino, T., 286
Randhawa, P., 354
Ranich, T., 839
Rantala, A., 1208
Rao, P.S., 5:29
Ravindran, A., 5:E29
Raynaud, A., 302
Razeghi, P., 867
Reblin, T., 619
Reboldi, G., 371
Reddan, D.N., 57, 182
Reed, A.I., 31
Reeve, S., 144
Regnard, J., 664, 668, 696
Reilly, R.F., 4:E23
Reisin, E., 1129
Remuzzi, G., 196
Rérolle, J-P., 302
Revelo, M. P., 1329
Reydel, K., 518
Reynolds, J., 1324
Ribbe, E., 377
Richardson, D., 109
Rizza, V., 240
Robino, C., 2:E7
Robinson, C., 523
Rocco, M.V., 813
Rodby, R.A., S1:191
Rodicio, J.L., 640
Roel, J. P., 1065
Rogerson, M., 42
Romano, M., S1:85
Rosa, V.D., 339
Rossi, F., S1:38
Rossing, P., 1376
Roszman, T., 6:E36
Rovere, G., 3:E11
Roys, E., 1240
Rubin, J. M., 935
Rudolph, P., 1026
Russell, R.R., 792
Russo, D., 18
Ruthazer, R., 777, 803
Ryschkewitsch, C.F., 354

Saab, S., 91
Sacerdoti, S., 3:E11
Sacks, S.H., 430
Sadler, J.H., 494
Sadow, J.L., 274
Saito, T., 1016
Sakai, H., 761
Sakai, N., 1169
Sakai, S., S1:107
Sakata, N., 1016
Sanaka, T., S1:212
Sangalli, L., 3:E11
Santoro, D., S1:115, 118
Saouaf, R., 658
Sasaki, S., S1:50
Sato, H., S1:182
Sato, M., S1:54
Sato, T., S1:168, 175
Satta, E., S1:85
Savica, V., S1:115, 118
Savige, J., 1217
Scanziani, R., 3:E11
Schell-Feith, E. A., 1229
Schenkel, F.A., 580
Schinzel, R., 785, S1:100
Schlöndorff, D., 1061
Schmeiser, H. H., 5:E26
Schmidt, R.J., 847
Schneeberger, H., 1061
Schneider, B., 118
Schneider, M., 867
Schreiber, M.J. Jr., S4:1, 37
Schröder, F.H., 331
Schulman, G., 1329
Scornik, J.C., 31
Sebekova, K., S1:100
Sedlacek, M., 560
Seguin, R., 42
Sekkarie, M., 36
Selhub, J., S1:91
Semplicini, A., 165
Serrano, P., 1108
Serrão, P., 502
Sesso, R., 249
Sharma, A.P., 488
Sharma, R.K., 488
Shearer, G. C., 1385
Shemin, D., 85, S1:91
Sherman, R.A., S4:18
Sheth, R.D., 553
Shetye, K.R., 205
Sheu, B-S., 98
Shibasaki, Y., 4:E19
Shigematsu, T., S1:152, 172, 175
Shilov, Y. M., 1026
Shima, M., S1:161
Shimizu, T., 4:E19
Shinohara, K., S1:186
Shinzato, T., S1:212
Shioi, A., S1:34, 47
Shoji, T., S1:4, 30, 186
Shokouh-Amiri, M.H., 132
Shu, K.-H., 1074
Siegal, B., 580
Signoriello, G., 18
Sika, M., 744
Sile, S., 4:E21
Silkensen, J., 1065
Singer, J., 1398
Sirois, I., 1271
Situlin, R., S1:63
Siu, Y.P., 256
Smith, A.I., 144
Smogorzewski, M.J., S1:122
Soares, V., 26
Soares-da-Silva, P., 502
Sobh, M. A., 1277
Soeters, P.B., 832
Soria, M. R., 1421
Sorof, J.M., 754
Soucie, J.M., 547
Speiser, W., 979
Spinello, M., 165
Spital, A., 189
Spittle, M. A., 1408
Sprague, S.M., S5:51
Stack, A. G., 992
Staessen, J. A., 1158
Stahl, R.A.K., 5:E27, 619
Stegall, M.D., S2:3
Stehouwer, C. D. A., 1376
Steiger, J., 3:E13
Sternby, J., 565
Stoner, G.L., 354
Stopper, H., 296
Stratta, R.J., 132
Strickland, T., 523
Sudo, S., 384
Suganami, T., S1:134
Sugar, L., 728
Sugawara, A., S1:134
Suh, H., 6:E37
Sunagawa, O., 64
Sunder-Plassmann, G., 77, S1:20, 956, 979
Surian, M., 3:E11
Suzuki, M., 4:E19, S1:147
Suzuki, S., 70
Swalsky, P.A., 354
Swartz, R. D., 935
Sweny, P., 631
Szczech, L.A., 57
Szelag, J-C., 510
Szeto, C.C., 9, 400

Taal, M. W., 1365
Tabata, T., S1:30
Tabei, K., S1:212
Taccetta, C., S5:57
Taguma, Y., 736
Tahara, H., S1:165
Tai, T.-Y., 1185
Takagi, H., S1:168
Takamitsu, Y., S1:95
Takasugi, M., S1:220
Takebayashi, S., 1016, 1082
Takeya, M., 1016
Tamaki, K., 1191
Tamano, M., 384
Tamashiro, M., 64
Tanaka, H., S1:50
Tanaka, I., S1:134
Tanaka, Y., S1:168
Tang, S., 317, 1055, 6:E38
Taniwaki, H., S1:47, 186
Tanner, G. A., 1089
Tanner, J. A., 1089

Taoka, M., S1:220
Tareeva, I. E., 1026
Tarng, D.-C., 941
Tarnow, L., 1376
Tashita, A., 265
Tattersall, J., 1277
Taub, K., 1122
Tedeschi, P.J., 824
Teerlink, T., 1376
Teodorescu, V., 560
Terada, Y., S1:50
Terrin, N.C., 777
Ter Wee, P.M., 858
Terzi, F., 652
Thaiss, F., 619
Thambyrajah, J., 537
Thomas, J. W., 1311
Thomas, L. L., 1414
Thompson, C., 1398
Thornhill-Joynes, M., 523
Thorp, M.L., 104
Tizzoni, L., 1158
Tobe, S., 1398
Toffelmire, E., 42
Tominaga, Y., S1:168, 175
Tomioka, S., 736
Tomosugi, N., 1169
Tong, K.-L., 1307
Tong, S.-F., 1307
Tordoir, J. P., 948
Townend, J.N., 537
Tozawa, M., 1235
Tray, K., 4:E23
Trofe, J., 132
Troyanov, S., 1271
Truog, R.D., 901
Tsai, D.-H., 1185
Tsai, W-J., 4:E17
Tsang, D.N.C., 127
Tsau, Y-K., 279
Tse, K.-C., 6:E38
Tulunay, Ö., 6:E34
Turgay, M., 1199
Tzamaloukas, A.H., 862

Uchida, K., S1:168, 175
Uesugi, N., 1016
Uhl, J.R., 4:E22
Unver, B., 979
Ura, S., 26
Uribarri, J., 518, 560

Valderrábano, F., 443
Van Der Heijden, B. J., 1229
Van Der Sande, F. M., 948
Van der Sande, F.M., 832
Van der Werf, W.J., 31
Van Ypersele De Strihou, C., 5:E26
Vasconcelos, E., 249
Vassalotti, J.A., 560
Vaziri, N.D., 1, S1:74
Veelken, R., 153
Velasquez Forero, E., S5:20
Velosa, J.A., S2:3
Vershvovsky, Y., 6:E37
Vienken, J., 296
Vigneault, N., 1271
Vijayan, A., 274
Vita, G., S1:118
Vlacich, V., 518
Vychytil, A., 77, 118, 956

Wada, T., 1169
Wagner, Z., 785
Wai-Yin Yu, A., 588
Wakugami, K., 1235
Wall, B.M., 4:E21
Waltzer, W., 6:E37
Wang, H., 1038
Wang, J.-G., 1158
Wang, J-S., 876
Wang, Y-L., 98
Wanner, C., S1:14
Ward, H.J., 523
Wasserstein, A.G., 406
Watanabe, I., S1:168, 175
Watanabe, Y.J., 249
Watson, B. Jr., 529
Weijmer, M.C., 858
Weiss, J., 426
Weitzel, W. F., 935, 1240
Wenk, R.E., 3:E12
Wheeler, D.C., 537
Wheeler, J.R.C., 824
Whelton, P.K., 49
White, P., 42
Will, E., 411
Will, E.J., 109
Williams, G.S., 658
Wilson, D., 1217
Wilson, R., 42
Winkelmayer, W. C., 1178
Winsett, R., 132
Witana, S.C., 523
Wittmann, I., 785
Wolf, G., 619, 5:E27
Wong, G., 2:E6
Wong, K.M., 127, 390
Wong, R.W.S., 256
Wright, J. Jr., 744
Wright, S., 339
Wu, K.-D., 1185
Wu, M.-J., 1074
Wu, M-L., 4:E17

Yahata, K., S1:134
Yamakawa, T., S1:208
Yamamoto, C., S1:220
Yamamoto, T., S1:161
Yamase, H., 4:E18
Yamashita, A.C., S1:217
Yanagisawa, N., S1:54
Yang, H-B., 98
Yang, W.-C., 941
Yaqoob, M. M., 6:E32
Yee, H.F. Jr., 91
Yee-Moon Wang, A., 1:E3, 588, 400
Yeh, J-H., 876
Yeh, M-Y., 876
Yeung, C.-K., 6:E38
Yilmaz, E., 6:E34
Yokoi, H., S1:134
Yokoyama, H., 1169
Yoon, S., 1298
Yoshida, H., 70
Yu, M-R., S1:204
Yudd, M., S5:45
Yuen, Y.-P., 1307
Yuk Hwa Wong, T., 1:E3
Yuk-Hwa Wong, T., 9, 400
Yuzawa, Y., 265

Zager, R.A., 339
Zappia, V., S1:85
Zaremba-Drobnik, D., S1:111
Zdunek, M. P., 1135
Zekonis, M., 792
Zerbini, G., 465
Zhang, R., 6:E33
Zhao, Z. H., 1414
Zhou, W., 430
Ziyadeh, F.N., 887

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.
Page references to Supplement 1 (October 2001), Supplement 2 (October 2001), Supplement 3 (October 2001), Supplement 4 (October 2001), Supplement 5 (November 2001), and Supplement 6 (December 2001) are preceded, respectively, by S1:, S2:, S3:, S4:, S5:, and S6:.

AASK (African-American Study of Hypertension and Kidney Disease), 744-753
Absorptiometry, in children after renal transplantation, 366-370
AcSDKP (*N*-acetyl-seryl-aspartyl-lysyl-proline), in chronic renal failure with erythropoeitin therapy, 510-517, 649-651
Acute coronary syndrome, end-stage renal disease mortality, interdialytic hypotension and, S4:1-10
Acute myelocytic leukemia history, familial Mediterranean fever with amyloidosis and, 6:E34
Acute myocardial infarction
  in end-stage renal disease, S1:26-29
  end-stage renal disease incidence after, 1235-1239
Acute renal failure (ARF)
  after monensin ingestion, 1108-1112
  after wasp stings, 6:E33
  apoptosis after, hepatocyte growth factor inhibition of, 274-278
  in cadaveric renal allograft with ranitidine-induced interstitial nephritis, 169-172
  in Crohn's disease treated with 5-aminosalicylic acid, 205-209
  ethylene glycol-mediated, 339-348
  in familial Mediterranean fever with amyloidosis and polyglandular endocrine failure, 6:E39
  indinavir-induced, risk factors for, 4:E23
  in intensive care unit, nephrologist role in, 426-429
  postischemic, protection by systemic adenosine, 610-618
  secondary to spontaneous acute tumor lysis syndrome in myelofibrosis, 4:E21
Acute tumor lysis syndrome, in myelofibrosis with secondary ARF, 4:E21
α-Adducin gene, kidney function and, 1158-1168
Adenine phosphoribosyltransferase deficiency, in Iceland, 473-480
Adenosine
  in intradialytic hypotension, S4:11-17
  postischemic, protection of renal function and, 610-618
Adenosine diphosphate, platelet aggregation in chronic renal failure and, S1:111-114
Adequacy
  artificial intelligence for prescription/monitoring of hemodialysis, 1277-1283
  duration of dialysis and, 813-823
  frequent hemodialysis and, 225-239
  ionic dialysance relationship to in vivo urea clearance, 565-574
  simplified citrate anticoagulation for high-flux hemodialysis, 979-987
ADPKD. *See* Autosomal dominant polycystic kidney disease
Advanced glycation end products (AGEs)
  in diabetic nephropathy
    with adynamic bone, S1:161-164
    on peritoneal dialysis, S1:200-203
    progression and, 785-791
  induced cell-cycle dependent cellular proliferation and, 1096-1104
  peritoneal membrane properties in peritoneal dialysis, S1:107-110
  in progressive renal disease, S1:100-106, 785-791
African Americans
  with hypertension-related ESRD, 523-528
    mitochondrial DNA mutations in, 529-536
    renal function measurements in, 744-753
  renal transplant recipients
    maintenance immunosuppression for, S6:25-35
    TOR inhibitors and other immunosuppressive regimens for, S2:11-15
African-American Study of Hypertension and Kidney Disease (AASK), 744-753
Age
  alterations of vitronectin and α_v-integrin in nephropathy, 1298-1306
  ESRD incidence after stroke and acute myocardial infarction and, 1235-1239
  at onset of end-stage renal failure, dialytic survival and, 547-552
  renal dopaminergic activity in heart failure and, 502-509
AGEs. *See* Advanced glycation end products
Albumin, serum
  duration of dialysis and, 813-823
  excretion, immune-unreactive in diabetic rats, 144-152
  low levels, cardiovascular disease in ESRD and, S1:38-46
  optimally programmed hemodiafiltration therapy and, S1:220-223
  in PTECs, aquaporins and, 317-330
  synthesis in metabolic acidosis, 1199-1207
  tubular reabsorption and handling, 196-204
Albuminuria
  in diabetes, ghost albumin as marker for, 144-152
  renal disease progression in diabetes and hypertension, 1372-1375
Aldosterone synthase gene, kidney function and, 1158-1168
Algorithm, for erectile dysfunction evaluation in dialysis, S1:115-117
Alkaline phosphatase
  correlation with whole *vs.* intact parathyroid assay, S1:172-174

in hemodialyzed diabetic patients, S1:139-142
Allelic loss, in tumorigenesis, S1:165-167
Allergic interstitial nephritis, after wasp stings, 6:E33
Allograft
cadaveric, rapid recurrence of ANCA-negative pauci-immune vasculitis after, 1:E3
dysfunction
novel etiology of, 658-663
prediction, serum creatinine monitoring methods for, 1065-1073
polyomavirus-associated interstitial nephritis, molecular genotyping of, 354-365
with pulmonary mucormycosis, combined medical surgical therapy for, 6:E37
recurrent immunoglobulin A nephropathy in, 588-596
rejection
during cyclosporine withdrawal, sirolimus effect on, S2:3-10
outcomes, 31-35
ranitidine-induced acute interstitial nephritis, 169-172
risk factors for, S6:44-50
treatment, S6:2-9
Alport's syndrome, phenotypes of X-linked and autosomal recessive carriers, 1217-1228
Ambulatory blood pressure monitoring, lisinopril therapy for hemodialysis hypertension and, 1245-1250
Aminoguanidine, red cell deformability in diabetic azotemic and uremic patients and, 14114-1420
5-Aminosalicylic acid, ARF development in Crohn's disease and, 205-209
Aminotransferase activity, in chronic renal failure, 1009-1015
Amiodipine, *vs.* mixed L- and T-type calcium channel blocker in hypertension, 1292-1297
Amlodipine, *vs.* irbesartan for type 2 diabetic nephropathy, S1:191-194
Amphotericin B, for diabetic renal allograft recipient with pulmonary mucormycosis, 6:E37
Amyloid nephropathy, in familial Mediterranean fever, 6:E34
Amyloidosis
in familial Mediterranean fever, 6:E34
in leprosy, 26-30
secondary
causing nephrotic syndrome in elderly female, 437-440
to familial Mediterranean fever, polyglandular endocrine failure in, 6:E39
ANCA-positive vasculitis
in cytomegalovirus infection with thrombosis, 5:E27
in Greek siblings with chronic silica exposure, 5:E28
Anemia
with cardiovascular disease
in end-stage renal disease, S1:38-46
erythropoietin effect on, S1:20-25
cerebral oxygen metabolism and, S1:129-133
duration of dialysis and, 813-823
as early complication, 803-812
erythropoetin therapy. *See* Erythropoietin
of erythropoietin deficiency, in nephrotic syndrome, 1-8
frequent hemodialysis and, 225-239
with iron-deficiency, transferrinuria in, 1-8
iron therapy for. *See* Iron therapy
novel erythropoiesis stimulating protein for, 1390-1397
prognosis for, 1334-1336
Angiotensin-converting enzyme gene polymorphism
macroangiopathy in diabetic nephropathy and, 9-17
renal function and, 1158-1168
Angiotensin-converting enzyme inhibitors
with AT1-receptor antagonists for IgA nephropathy, 18-25
erythropoeitin responsiveness and, 510-517, 649-651
for hemodialysis hypertension, 1245-1250
prolonged survival of arteriovenous grafts and, 1240-1244
renoprotection in nondiabetic chronic renal failure, 1365-1371
Angiotensin II receptor blocker
with ACE inhibitors, for Ig A nephropathy, 182-185
renoprotection in nondiabetic chronic renal failure, 1365-1371
vs. calcium channel blocker for type 2 diabetic nephropathy, S1:191-194
Angiotensinogen *M235T* gene polymorphism, macroangiopathy in diabetic nephropathy and, 9-17
AN-69 membrane, hypersensitivity reactions, 173-178
Antidepressant, interaction with cyclosporine, 1105-1107
Antihypertensive therapy. *See also specific type of antidepressant drugs*
for immunoglobulin A nephropathy, 182-185
withholding for intradialytic hypotension reduction, S4:18-25
Antiproteinuric effect, of angiotensin II receptor blockers with ACE inhibitors, 182-185
Aortic regurgitation, in adult polycystic kidney disease, 1208-1216
Apolipoproteins
ApoE, in chylomicrons in Heymann's nephritis, 1385-1389
renal handling in rats, 619-630
Apoptosis
in coronary artery disease with ESRD, soluble Fas as marker for, 1271-1276
hepatocyte growth factor inhibition of, 274-278
Mönckeberg's medial sclerosis in end-stage renal disease and, S1:S47-49
soluable Fas and hyaluronan effects on, S1:54-57
Aquaporins, in PTECs, transferrin upregulation and, 317-330
ARF. *See* Acute renal failure
L-Arginine availability, in chronic renal failure, nitric oxide metabolism and, S1:74-79
Aristolochic acid nephropathy
in Chinese patient, 5:E26
Arrhythmias
in chronic hemodialysis, cisapride effects on, 1284-1281
end-stage renal disease mortality, interdialytic hypotension and, S4:1-10
Arteriosclerosis, nitric oxide metabolism in chronic renal failure and, S1:74-79
Arteriovenous access
fistula placement, preoperative vascular mapping for, 560-564
infected, clinical consequences of, 975-978
prolonged survival, ACE inhibitors and, 1240-1244

use, timing of nephrologist referral and, 494-501
Artificial intelligence, for prescription/monitoring of hemodialysis, 1277-1283
Atherosclerosis
in end-stage renal disease, S1:30-33
cardiovascular mortality and, S1:4-7
soluble Fas as marker for, 1271-1276
in hemodialysis patients, protective effect of CETP in, 70-76
renal disease progression in type 2 diabetes and, S1:186-190
AT1-receptor antagonists, with ACE inhibitors, for IgA nephropathy, 18-25
Atrial thrombosis, central venous dialysis catheters and, 631-639
Atriovenous fistulas, stenotic, calcium phosphate depositions in, 377-383
Autograft, with total parathyroidectomy for hyperparathyroidism, S1:168-171
Autoimmune glomerulonephritis, T-cell-specific therapy in, 1321-1328
Automated peritoneal dialysis, preceding exchange with polyglucose *vs.* glucose, 118-126
Autonomic nervous system dysfunction, in uremia, S1:118-121
Autoregulation dysfunction, ESRD mortality, interdialytic hypotension and, S4:1-10
Autosomal dominant polycystic kidney disease (ADPKD)
exacerbation of hypertension by chronic caffeine consumption, 1089-1095
family clustering of ruptured intracranial aneurysms in, 770-776
polycystin-1 characterization in, 1421-1429
survival after end-stage renal disease, 777-784
Azathioprine
adjuvant, for immunosuppression maintenance, S6:25-35
with cyclophosphamide for diffuse proliferative lupus glomerulonephritis, 256-264
with sirolimus and corticosteroids for renal transplant immunosuppression, S2:16-21
toxicity, fibrosing cholestatic hepatitis-like syndrome from, 640-645

Bartter's syndrome variant, progression to end-stage renal disease, 165-168
Base therapy, for sever acidemic states, 703-727
Basic fibroblast growth factor-2, regulation in proximal tubular epithelial cells by heparin, 587-609
Bee stings, acute allergic interstitial nephritis after, 6:E33
Benign nephrosclerosis, iron deposition in renal biopsy specimens, 1038-1044
Beriberi, and unexplained encephalopathy in dialysis, 941-947
Bicarbonate
buffer *vs.* lactate buffer, for peritoneal dialysis fluid, 867-875
in dialysate, intradialytic hypotension reduction and, S4:18-25
for severe acidemic states, 703-727
Biliary atresia, nephromegaly and elevated HGF/TGFβ_1 in, 279-285
Bioimpedance spectroscopy, of body water compartments in hemodialysis, 832-838
Biomineralization, inorganic phosphate and, S1:34-37
Birth weight, as risk factor for proteinuria in multiracial pediatric population, 1045-1054
BK virus molecular genotyping, in human polyomavirus-associated interstitial nephritis after renal transplantation, 354-365
Black Americans. *See* African Americans
Bladder drainage, long-term outcome for kidney-pancreas transplantation and, 132-143
Blood pressure. *See also* Hypertension; Intradialytic hypotension
ambulatory monitoring, lisinopril therapy for hemodialysis hypertension and, 1245-1250
control, frequent hemodialysis and, 225-239
glomerular, calcium channel blocker effects on, 1292-1297
low body weight as risk factor for proteinuria and, 1045-1054
selective cyclooxygenase-2 inhibitors and, 1145-1157
Blood pressure medications. *See* Antihypertensive therapy
Blood volume, in intradialytic hypotension, S4:11-17
Body composition, of children after renal transplantation, 366-370
Body fluid regulation, during microgravity, 684-690
Body mass
cardiovascular mortality in end-stage renal disease and, S1:4-7
changes, during space flights, 691-695
determination, in children after renal transplantation, 366-370
in male hemodialysis patients, changes in diabetics *vs.* nondiabetics, S1:208-211
Body water compartments, in hemodialysis, bioimpedance spectroscopy of, 832-838
Body weight
gain, in renal transplant recipients, 349-353, 409-410
low, as risk factor for proteinuria in multiracial pediatric population, 1045-1054
management, for renal transplant recipients, S6:10-24
Bone cyst, in dialysis-related amyloid osteopathy, S1:156-160
Bone disease. *See also* Renal osteodystrophy
AGEs in diabetic nephropathy and, S1:161-164
minimizing, strategies for, 1430-1436
in renal transplant recipients, management of, S6:10-24
in uremia, skeletal resistance to parathyroid hormone and, S1:152-155
Bone mineral density, of children after renal transplantation, 366-370
Bone resorption, in dialysis-related amyloid osteopathy, S1:156-160
Bradycardia, in intradialytic hypotension, S4:11-17
Bradykinin, AN-69 membrane hypersensitivity reactions and, 173-178
Brain
dysfunction, in chronic renal failure, S1:122-128
oxygen metabolism, in chronic renal failure, S1:129-133
Britain, referral decisions, factors affecting, 42-48

Bronchiectasis, secondary amyloidosis in nephrotic syndrome and, 437-440
Brushite precipitation, in venous-access stenosis, 377-383
Buffers, comparison for peritoneal dialysis fluid, 867-875

Cadmium exposure, end-stage renal disease and, 1001-1008
Caffeine
  chronic consumption, exacerbation of hypertension in ADPKD, 1089-1095
  for intradialytic hypotension, S4:26-36
Calcifications, in stenotic atriovenous fistulas, 377-383
Calcineurin inhibitors. *See also specific calcineurin inhibitors*
  adverse events in renal transplant recipients, S6:25-35
Calcipotriol, therapeutic uses of, S5:3-19
Calcitriol
  hemodialysis mortality risk, vitamin D gene receptor gene polymorphisms and, 965-974
  immunomodulatory effects, 792-802
  oral *vs.* intravenous therapy for dialysis patients, S5:41-44
  parathyroid hormone suppression, *vs.* paricalcitol, S5:51-56
  resistance in secondary hyperparathyroidism, paricalcitol for, S5:45-50
  for secondary hyperparathyroidism in chronic renal failure, S5:20-33
Calcium. *See also* Hypercalcemia
  control, to minimized bone disease in renal failure, 1430-1436
  in dialysate, intradialytic hypotension reduction and, S4:18-25
  homeostasis, paricalcitol and, 792-802
  intracellular, AGEs in adynamic bone disease with diabetic nephropathy, S1:161-164
  neurotoxicity, in chronic renal failure and, S1:122-128
Calcium channel blockers
  L-type *vs.* mixed L-and T-type for hypertension, 1292-1297
  vs. irbesartan for type 2 diabetic nephropathy, S1:191-194
Calcium oxalate crystals
  binding/processing in cytokine induction, 331-338
  kinetics, in urine of preterm neonates, 1229-1234
Calcium phosphate depositions, in stenotic atriovenous fistulas, 377-383
Canada
  factors affecting referral decisions, 42-48
  nonreferral to dialysis, 36-41
Cancer
  in renal transplant recipients, management of, S6:10-24
  vitamin D analogues for, S5:3-19
CAPD. *See* Continuous ambulatory peritoneal dialysis
Ca^{2+} pump activity, low, in diabetic nephropathy, 465-472
Carbicarb, for severe acidemic states, 703-727
Carboxymethyllysine
  in diabetic nephropathy progression, 1016-1025
  progression of diabetic nephropathy and, 785-791
  in progressive renal disease, S1:100-106
Cardiac death, of hemodialysis patients, erythropoietin effect on, S1:20-25
Cardiopulmonary resuscitation (CPR)
  in dialysis unit, patient attitudes toward, 847-852
  for renal disease patients, 884-886
Cardiovascular disease. *See also specific cardiovascular diseases*
  with chronic kidney disease, prevalence and risk factors for, 1398-1407
  in end-stage renal disease, risk factors for, S1:26-29, S1:38-46
  erythropoietin effect on, S1:20-25
  hemodialyzed diabetic nephropathy patients and, S1:195-199
  nitric oxide metabolism in chronic renal failure and, S1:74-79
  and proteinuria, S1:8-13
  with renal failure, metabolic pathogenesis of, 1372-1375
  in renal transplant recipient, S6:10-24, 36-43
  risk factors, in chronic renal failure, 537-546
  valvular abnormalities, in adult polycystic kidney disease, 1208-1216
Cardiovascular reflex tests, in chronic renal failure, S1:118-121
Carnitine
  for intradialytic hypotension, S4:26-36
  metabolism, in chronic renal failure, S1:63-67
Carotid artery intima-media thickness, renal disease progression in type 2 diabetes and, S1:186-190
Case-control studies
  ESRD risk with drug abuse, 49-56
  of revascularization in ESRD patients, 57-63
Catheters, dialysis
  atrial thrombosis in, 631-639
  fracture, scanning electron microscopy of, 858-861
  infected arteriovenous grafts and, 975-978
  spontaneous fracture and embolization into pulmonary artery, 1311-1315
  Tesio, usage in children, 553-559
CD26/B 7 costimulation, for autoimmune glomerulonephritis, 1321-1328
CD4+T cells, minocycline induced, 6:E36
Cefepime, *vs.* vancomycin with netilmicin for CAPD-associated peritonitis, 127-131
Cellulose dialysis membrane, suppression of complement activation, 384-389
Central nervous system dysfunction, in chronic renal failure, S1:122-128
Central venous dialysis catheters, atrial thrombosis and, 631-639
Cerebral oxygen metabolism, in chronic renal failure, S1:129-133
Chemokines, in crescentic glomerulonephritis, 1169-1177
Children
  AN-69 membrane hypersensitivity reactions, 173-178
  body composition after renal transplantation, 366-370
  on chronic hemodialysis, Tesio catheter usage for, 553-559
  long-term cyclosporine treatment for focal segmental glomerulosclerosis in, 754-760
  multiracial population, low body weight as risk factor for proteinuria, 1045-1054
  renal transplant recipients
    discontinuing immunosuppression in, 901-915
    safety/efficacy of TOR inhibitors for, S2:22-28

Chinese patients
aristolochic acid nephropathy in, 5:E26
primary hyperoxaluria type 2 with novel *GRHPR* gene mutation in, 1307-1310
recurrent immunoglobulin A nephropathy in renal transplant allografts, 588-596
undergoing CAPD, tuberculosis infection in, 1055-1060
Choices for Healthy Outcomes in Caring for End-Stage Renal Disease Center Study (CHOICE), 494-501
Cholesterol
cardiovascular mortality in end-stage renal disease and, S1:4-7
metabolism in uremia, impact on cardiovascular disease, S1:14-19
Cholesteryl ester transfer protein, vascular disease prevention in hemodialysis and, 70-76
Chromosome allelic losses, in tumorigenesis, S1:165-167
Chronic allograft nephropathy, long-term renal transplantation survival and, S6:44-50
Chronic renal failure (CRF). *See also* End-stage renal disease
in adenine phosphoribosyltransferase deficiency in Iceland, 473-480
anemia of. *See* Anemia
autonomic dysfunction in, S1:118-121
bone turnover, skeletal resistance to parathyroid hormone and, S1:152-155
with cardiovascular disease, prevalence and risk factors for, 1398-1407
cardiovascular mortality, microalbuminemia/proteinuria and, S1:8-13
cardiovascular risk factors in, 537-546
carnitine metabolism in, S1:63-67
central nervous system dysfunction in, S1:122-128
congestive heart failure in, 992-1000
delayed nephrologist referral, determinants of, 1178-1184
depressed cerebral oxygen metabolism in, S1:129-133
dyslipidemia progression, in chronic hemodialysis, 64-69
endothelial dysfunction with sulfur amino acid metabolism in, S1:95-99
erythropoeitin therapy, AcSDKP levels in, 510-517
Fas antigen acceleration of mononuclear cell adhesion, S1:54-57
in Gitelman's syndrome, peritoneal dialysis for, 165-168
identification of genomic damage to lymphocytes in, 296-301
insulin secretion in, S1:58-62
in intensive care unit, nephrologist role in, 426-429
Medicare expenditures, geographic variation in, 824-831
nitric oxide metabolism and, S1:74-79
nondiabetic, achieving maximal renal protection in, 1365-1371
progression. *See* Progression, of chronic renal failure
prostaglandin metabolism and platelet aggregation in, S1:111-114
quality of life in, 443-464
reduced aminotransferase activity in, 1009-1015
referral decisions and, 42-48
risk, recreational drug use and, 49-56
secondary hyperparathyroidism in. *See* Hyperparathyroidism, secondary
thyroid function in, S1:80-84
Chylomicrons, alteration of endothelial binding in Heymann's nephritis, 1385-1389
Chyloperitoneum
in peritoneal dialysis, 3:E12
Cisapride, QT interval and QT dispersion in chronic hemodialysis and, 1284-1281
Citrate
calcium oxalate monohydrate crystallization kinetics and, 1229-1234
simplified anticoagulation, for high-flux hemodialysis, 979-987
Clinical trial design, pharmaceutical companies and, 1113
Cocaine, hypertension-associated end-stage renal disease and, 523-528
Cockroft-Gault formula, systematic error of, 862-866
Collagen, AGEs in adynamic bone disease of diabetic nephropathy, S1:161-164
Collagen glomerulopathy, type III, 4:E15
Collapsing glomerulopathy, 5:E24
Comet-assay analysis, identification of genomic lymphocyte damage in uremia, 296-301
Common variable immunodeficiency, with granulomatous renal disease, 2:E7
Comorbidity, quality of life for renal transplant recipients and, 580-587
Complement
activation
after hemodialysis, suppression by cellulose dialysis membrane, 384-389
lectin pathway-mediated in IgA glomerulonephritis, 1082-1088
renal ischemia-reperfusion injury and, 430-436
Congestive heart failure
dialytic survival in end-stage renal disease and, 547-552
prevalence/correlates in dialysis patients, 992-1000
Connective tissue disease growth factor, in profibrotic action of transforming growth factor-β, S1:134-138
Continuing medical education exercises, 1:E2, 2:E5, 3:E10, 4:E16, 5:E25, 6:E31
Continuous ambulatory peritoneal dialysis (CAPD)
carnitine metabolism in, S1:63-67
for Chinese patients, tuberculosis infection in, 1055-1060
for chronic renal failure, platelet aggregation and prostaglandin metabolism in, S1:111-114
hemoperitoneum causing hepatocarcinoma treated with percutaneous embolization, 3:E11
imidazolone localization in peritoneum, S1:107-110
peritonitis, cefepime *vs.* vancomycin with netilmicin for, 127-131
preceding exchange with polyglucose *vs.* glucose, peritoneal equilibration results and, 118-126
Continuous renal replacement therapy, AN-69 membrane hypersensitivity reactions, 173-178
Coronary artery bypass, cardiovascular disease in ESRD and, S1:38-46
Coronary artery disease
calcification progression, in chronic hemodialysis, 64-69
in end-stage renal disease, soluble Fas as marker for, 1271-1276

Corticosteroids
for minocycline-induced interstitial nephritis, hepatic failure and systemic eosinophilia, 6:E36
for renal transplant recipients
as adjunctive immunosuppression maintenance, S6: 25-35
African-American, S2:11-15
with calcineurin-free immunosuppression, S2:16-21
pediatric body composition and, 366-370
Costs/cost analysis, for end-stage renal disease, geographic variation in, 824-831
Cough medicine abuse, hypokalemic metabolic alkalosis from, 390-394
CPR. *See* Cardiopulmonary resuscitation
C-reactive protein
cardiovascular disease in end-stage renal disease and, S1: 38-46
hemodialysis outcome and, 1408-1413
Creatinine, serum
excretion, in continuous peritoneal dialysis, 862-866
graft dysfunction and, S6:44-50
with low-flux *vs.* high-flux hemodialyzers, 575-579
as marker for renal impairment in diabetes mellitus, 310-316
monitoring methods to predict late allograft failure, 1065-1073
in poststreptococcal acute glomerulonephritis follow-up, 249-255
production/excretion in end-stage renal disease, 1119-1121
prostaglandin metabolism and platelet aggregation in CRF and, S1:111-114
ratio to dialysate, during postpolyglucose exchange, 118-126
Creatinine clearance
diabetic nephropathy progression, advanced glycation end products and, 785-791
effect of increased dialysate flow rate in low-flux *vs.* high-flux dialyzers, 575-579
for late allograft failure prediction, 1065-1073
during peritoneal equilibration test after polyglucose exchange, 118-126
in poststreptococcal acute glomerulonephritis follow-up, 249-255
Crescentic glomerulonephritis, p38 mitogen-activated protein kinase in, 1169-1177
CRF. *See* Chronic renal failure
Crohn's disease, 5-aminosalicylic acid for ARF development and, 205-209
β-Crosslaps, in hemodialyzed diabetic patients, S1:139-142
Cryoglobulinemia, with membranoproliferative glomerulonephritis, interferon-α with ribavirin for, 6:E35
Cubilin, mediation of proximal tubule albumin reabsorption, 196-204
Cyclin D1, AGE-induced cell-cycle dependent cellular proliferation and, 1096-1104
Cyclooxygenase-2 inhibitors, selective, renal and cardiovascular effects of, 1145-1157
Cyclophosphamide, for diffuse proliferative lupus glomerulonephritis, 256-264
Cyclosporine
immunosuppression, S6:2-9
interaction with St. John's wort after renal transplantation, 1105-1107
long-term treatment for focal segmental glomerulosclerosis in children, 754-760
maintenance, for renal transplant recipients, S6:25-35
osteoprotegerin levels after renal transplantation and, S1: 175-177
withdrawal, in presence of TOR inhibitors, S2:3-10
Cystatin C, in detecting renal impairment in diabetes, 310-316
Cystosolic calcium, insulin secretion in chronic renal failure and, S1:58-62
Cytokines. *See also specific cytokines*
in dialysis-related amyloid osteopathy, S1:156-160
induced production in cultured macrophages, 331-338
muscle loss in kidney disease and, 1337-1342
regulation in proximal tubular epithelial cells by heparin, 587-609
release in uremia, Th2 phenotype and, 286-295
Cytomegalovirus infection
in ANCA-positive vasculitis with thrombosis, 5:E27
fibrosing cholestatic hepatitis-like syndrome from, 640-645

Darbepoetin alfa, for anemia of chronic renal failure, 1390-1397
Decision analysis, hepatitis C virus screening strategies for hemodialysis, 91-97
Delivery of services, referral decisions and, 42-48
Deoxycorticosterone acetate-salt glomerulosclerosis, macrophage infiltration and glomerular osteopontin expression in, 153-164
3-Deoxyglucosone, ultrafiltration capacity of peritoneal membrane in CAPD patients, S1:107-110
Deoxypyridinoline, in hemodialyzed diabetic patients, S1: 139-142
Depression, of patient and spouse, in end-stage renal disease, 839-846
Destructive spondyloarthropathy, in dialysis-related amyloid osteopathy, S1:156-160
Diabetes mellitus. *See also* Diabetic nephropathy
after revascularization in ESRD, 57-63
cultured human skin fibroblasts in, for phenotypic assessment, 465-472, 646-648
experimental
alterations of vitronectin and α_v-integrin in, 1298-1306
ghost albumin excretion in, 114-152
streptozotocin-induced. *See* Rats, streptozotocin-induced diabetic
Diabetic nephropathy
AGE-induced cell-cycle dependent cellular proliferation in, 1096-1104
detection of, 310-316
in end-stage renal disease, 547-552, S1:26-29
erythropoietin effects on red cell deformability in, 14114-1420
family history, dialytic survival and, 547-552
hemodialysis for, S1:195-199
body fat mass changes in males and, S1:208-211

bone metabolism biochemical markers and, S1:139-142
survival in end-stage renal disease and, 547-552
insulin-dependent, low Ca^{2+} pump activity in, 465-472
macroangiopathy, ACE gene polymorphisms and, 9-17
oxidative stress activation of protein kinase C in, S1:204-207
peritoneal dialysis for, S1:200-203
platelet collagen receptor $\alpha 2\beta 1$ integrin and glycoprotein IIIa $PI^{A1/A2}$ polymorphism and, 1185-1190
progression. *See* Progression, of diabetic nephropathy
in renal transplant recipients
management of, S6:10-24
with pulmonary mucormycosis, combined medical surgical therapy for, 6:E37
responsiveness to recombinant erythropoietin and, 518-522
transforming growth factor-β as treatment target, 887-892
type 2
calcium channel blockade *vs.* irbesartan for, S1:191-194
macroangiopathy, ACE gene polymorphisms and, 9-17
platelet glycoprotein receptors in, 1185-1190
vascular access placement with preoperative noninvasive vascular mapping, 560-564
Diacylglycerol, progression of diabetic nephropathy and, S1:178-181
Diagnostic algorithm, for evaluation of erectile dysfunction in dialysis, S1:115-117
Dialysate
composition
in case-based approach for intradialytic hypotension, S4:37-47
for intradialytic hypotension reduction, S4:18-25
flow rate
increased, MTAC and urea Kt/V for low-flux *vs.* high-flux dialyzers, 575-579
variable Doppler *vs.* ultrasound dilution measurements of, 935-940
temperature, for intradialytic hypotension reduction, S4:18-25
Dialysis. *See also specific dialysis modality*
adequacy. *See* Adequacy
after revascularization in ESRD, 57-63
dose, optimizing by increasing blood flow rate in suboptimal vascular access, 948-955
duration, adequacy of dialysis and, 813-823
for hypertension-related end-stage renal disease, cocaine and, 523-528
maintenance, clinical outcome, effects of nutrition and inflammation on, 1343-1350
nonreferral and nonacceptance to, 36-41
outcome prediction, malnutrition-inflammation score and, 1251-1263
prescription modification for intradialytic hypotension reduction, S4:18-25
quality of life in, 443-464
referral decisions, factors affecting, 42-48
sexual dysfunction from, S1:115-117
survival
after ESRD in autosomal dominant polycystic kidney disease, 777-784
family history of ESRD and, 547-552
thiamine deficiency and unexplained encephalopathy in, 941-947
time shift, responsiveness to recombinant erythropoietin and, 518-522
Dialysis catheters. *See* Catheters, dialysis
Dialysis hypotension. *See* Intradialytic hypotension
Dialysis membranes
hypersensitivity reactions, 173-178
for removal of middle molecule uremic toxins, S1:217-219
Dialysis-related amyloidosis, hemodiafiltration therapy with hemodialysis and β_2-microglobulin absorption therapy for, S1:212-216
Dialysis-related amyloid osteopathy, osteoclastogenesis and osteoclast activation in, S1:156-160
Dialysis unit, cardiopulmonary resuscitation in, patient attitudes toward, 847-852
Dialyzers
high-flux, MTAC and urea Kt/V increases and, 575-579
membranes for. *See* Dialysis membranes
Dibutyryl cyclic adenosine monophosphate, for renoprotection after ischemia, 610-618
Diffuse proliferative lupus glomerulonephritis, IV *vs.* oral cyclophosphamide for, 256-264
2-8-Dihydroadeniuria, in adenine phosphoribosyltransferase deficiency in Iceland, 473-480
1,25-Dihydroxyvitamin D_3, gene polymorphisms, hemodialysis survival and, 965-974
Diphtheria vaccination, antibody response in hemodialysis patients, 1264-1270
Disseminated tuberculosis-associated hemophagocytic syndrome, with multiple organ dysfunction, 4:E19
Distal renal tubular acidosis, after posterior urethra valve surgery , prognostic factors for, 488-493
Diuresis
ground-based simulations, revised hypothesis from, 696-698
in space flights, 675-678
Diurnal variation, in responsiveness to recombinant erythropoietin and, 518-522
DNA analysis
of adenine phosphoribosyltransferase deficiency in Iceland, 473-480
of Chinese patient with primary hyperoxaluria type 2, 1307-1310
comet-assay in uremia, 296-301
in post-transplant polyomavirus-associated interstitial nephritis, 354-365
DNA mutations, in African Americans with hypertension-associated ESRD, 529-536
DNA replication, in kidney diseases, 1026-1037
DNA toposiomerases, in kidney diseases, 1026-1037
L-Dopa, urinary excretion in heart failure, 502-509
Dopamine, renal synthesis in heart failure, 502-509
Dose-response, losartan, in nondiabetic patients with nephrotic range proteinuria, 1381-1384
Doxercalciferol
for hyperparathyroidism suppression, 1430-1436
for secondary hyperparathyroidism, S5:34-40
therapeutic uses of, S5:3-19

Drug abuse
cough medicine, hypokalemic metabolic alkalosis from, 390-394
end-stage renal disease risk and, 49-56
Drug companies, clinical trial design and, 1113
Drug interactions
with calcineurin inhibitors, in renal transplant recipients, S6:25-35
cyclosporine-St. John's wort after renal transplanation, 1105-1107
of renal transplant recipients, S6:10-24
Drug therapy. *See also specific drugs*
for renal transplant recipients, S6:10-24
Dual x-ray absorptiometry, of body fat mass changes in hemodialysis patients, S1:208-211
Duplex ultrasound, vascular mapping, for arteriovenous fistula placement, 560-564
Dyslipidemia
cardiovascular disease in ESRD and, S1:38-46
cardiovascular mortality in renal disease and, S1:8-13
in chronic hemodialysis, 64-69
with kidney disease, prognosis for, 1334-1336
renal disease progression and, 64-69, 1372-1375

Echocardiography, of adult polycystic kidney disease, 1208-1216
Economic evaluation, of early *vs.* late referral for progressive renal failure, 1122-1128
Electroencephalogram, of nonconvulsive status epilepticus in peritoneal dialysis patient, 400-405
Electron-beam computed tomography, of coronary artery calcification progression in chronic hemodialysis, 64-69
Embolization, pulmonary artery, from spontaneous hemodialysis catheter fracture, 1311-1315
Emphysematous urinoma, in renal transplant recipients, 5:E29
Enalapril, with losartan, antiproteinuric effect in IgA nephropathy, 18-25
Encephalopathy, and thiamine deficiency in hemodialysis and peritoneal dialysis, 941-947
End-of-life issues, discontinuing immunosuppression in children with renal transplants, 901-915
Endothelial dysfunction, sulfur amino acid metabolism in chronic renal failure and, S1:95-99
End-stage renal disease (ESRD)
after stroke and myocardial infarction, 1235-1239
analytical methods, S3:204-230
atherogenic lipoproteins in, S1:30-33
in autosomal dominant polycystic kidney disease, survival after, 777-784
cadmium exposure and, 1001-1008
with cardiovascular disease
congestive heart failure, 992-1000
erythropoietin effect on, S1:20-25
mortality risk factors in, S1:4-7
risk factors for, S1:26-29
special studies for, S3:147-158
cardiovascular disease, risk factors for, S1:38-46
clinical indicators of care, S3:79-90
creatinine production/excretion in, 1119-1121
depression and marital dissatisfaction in, 839-846
with diabetes mellitus
erythropoietin effects on red cell deformability in, 14114-1420
hemodialysis for, S1:195-199
economic costs, S3:181-194
family history, prediction of dialytic survival and, 547-552
genomic damage in lymphocytes, identification of, 296-301
in Gitelman's syndrome, 165-168
hospitalization, S3:91-106
hyperhomocysteinemia treatment in, S1:91-94
with hypertension
cocaine usage and, 523-528
hypotension and sleep apnea in, S1:38-46
incidence, S3:37-52
inorganic phosphate, Mönckeberg's medial sclerosis and, S1:S47-49
in intensive care unit, nephrologist role in, 426-429
international comparisons, S3:195-200
lipoprotein metabolism, impact on cardiovascular disease, S1:14-19
Medicare expenditures, geographic variation in, 824-831
morbidity, S3:91-106
mortality, S3:135-146
cardiovascular risk factors and, S1:4-7
causes of, S3:135-146
interdialytic hypotension and, S4:1-10
muscle loss, activation of mechanisms in, 1337-1342
network definitions, S3:231
parathyroid hormone suppression, paricalcitol *vs.* calcitriol, S5:51-56
paricalcitol dosing by body weight or severity of hyperparathyroidism, S5:57-63
patient characteristics, S3:53-68
pediatric, S3:107-116
peritoneal dialysis, nonconvulsive status epilepticus in, 400-405
prevalence, S3:37-52
preventive health care measures, S3:159-168
provider characteristics, S3:169-180
quality of life in, 443-464
recombinant erythropoietin response, 518-522
referral
decisions, factors in, 42-48
early *vs.* late, economic evaluation of, 1122-1128
renal transplantation for, S3:117-134
revascularization, long-term outcomes of, 57-63
risk, recreational drug use and, 49-56
soluble Fas as marker for coronary artery disease, 1271-1276
survival, S3:135-146
terminology, S3:232-235
Th2 phenotype in, 286-295
treatment modalities, S3:69-78
vascular calcification, inorganic phosphate and, S1:34-37
Energy-dispersive spectrometry, of calcium phosphate depositions in stenotic atriovenous fistulas, 377-383
Energy metabolism, during space flights, 691-695

Enterococcal peritonitis, vancomycin-resistant, linezolid therapy for, 4:E20
Environmental exposure
to cadmium, end-stage renal disease and, 1001-1008
to silica, ANCA-positive vasculitis and, 5:E28
Eosinophilia
with hepatic failure and interstitial nephritis and after minocycline treatment, 6:E36
in ranitidine-induced acute interstitial nephritis in cadaveric renal allograft, 169-172
Ephedrine, for intradialytic hypotension, S4:26-36
Epidemic nephritis, follow-up of, 249-255
Epinephrine, during microgravity, 679-683
EPO. *See* Erythropoietin
Erectile dysfunction, in uremic dialysis patients, S1:115-117
Erythrocyte deformability, in diabetic azotemic and uremic patients, erythropoietin and, 1414-1420
Erythropoietin (EPO)
carnitine metabolism in chronic renal failure and, S1:63-67
for chronic renal failure, AcSDKP levels and, 510-517
deficiency, in nephrotic syndrome, 1-8
duration of dialysis and, 813-823
effect on cardiovascular disease, S1:20-25
gene transfer, ligand-regulated, S1:50-53
for hemodialysis patients, optimization of, 109-117
intravenous iron supplementation, safe dosing of, 988-991
metabolism, in nephrotic syndrome, 1-8
recombinant human
for anemia of chronic renal failure, 803-812
gender and diabetes effect on responsiveness to, 518-522
red cell deformability in diabetic azotemic and uremic patients, 14114-1420
responsiveness, ACE inhibitors and, 649-651
use of patient cohorts in establishing outcomes for, 415-425
Escherichia coli, urinary tract infection causing non-O157:H7 hemolytic uremic syndrome, 4:E22
ESRD. *See* End-stage renal disease
Ethical issues
cardiopulmonary resuscitation in dialysis unit, 847-852
discontinuing immunosuppression in children with renal transplants, 901-915
for living organ donation, 189-195
Ethnicity. *See also* African Americans; Chinese patients
ANCA-positive vasculitis in Greek siblings with chronic silica exposure, 5:E28
hemodiafiltration outcomes, S1:212-216
of pediatric population, low body weight as risk factor for proteinuria, 1045-1054
Ethylene glycol-mediated tubular injury, metabolites and injury pathways, 339-348
Everolimus, safety/efficacy for pediatric renal transplant recipients, S2:22-28
Extracellular fluid volume, in hemodialysis, bioimpedance spectroscopy of, 832-838
Extracellular signal-regulated kinase, progression of diabetic nephropathy and, S1:178-181
Factor H, after hemodialysis with cellulose membranes, 384-389
Familial Mediterranean fever, with amyloidosis, 6:E34
polyglandular endocrine failure in, 6:E39
Family history
of end-stage renal disease, prediction of dialytic survival and, 547-552
of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease, 770-776
Fas antigen
as coronary artery disease marker in end-stage renal disease, 1271-1276
in uremia, acceleration of mononuclear cell adhesion, S1:54-57
Fat body mass, of children after renal transplantation, 366-370
Femoral artery intima-media thickness
genetic factors in, 1158-1168
renal disease progression in type 2 diabetes and, S1:186-190
Ferritin, optimizing erythropoietin therapy for hemodialysis and, 109-117
Fibronectin, gene expression in renal fibrosis, S1:134-138
Fibrosing cholestatic hepatitis, in HBV-negative and HBC-negative renal transplant recipients, 640-645
F2-isoprostanes, in hemodialysis patients, 1408-1413
Fludrocortisone, for intradialytic hypotension, S4:26-36
Fluid balance
in hemodialysis, bioimpedance spectroscopy of, 832-838
and kidney function in space, 664-667
Foamy macrophages, in diabetic nephropathy progression, 1016-1025
Focal segmental glomerulonephritis, prediction of treatment response, 406-407
Focal segmental glomerulosclerosis
DNA topoisomerases in, 1026-1037
long-term cyclosporine treatment for children, 754-760
Folate (folic acid)
elevated homocysteine plasma levels and, 956-964
homocysteine levels in dialysis, *MTHFR* gene polymorphisms and, 77-84
for hyperhomocysteinemia treatment in end-stage renal disease, S1:91-94
Fulminant hepatic failure, in renal transplant recipients, lamivudine for, 1074-1081

Gabapentin, for restless legs syndrome in hemodialysis, 104-108
G200210A prothrombin gene mutation, Renal transplantation failure and, 1061-1064
Gender differences, in responsiveness to recombinant erythropoietin, 518-522
Gene mutations
in Chinese patient with primary hyperoxaluria type 2, 1307-1310
in familial Mediterranean fever with amyloidosis, 6:E34
increased rate of renal transplant failure and, 1061-1064
in *MEN1*-associated tumors, S1:165-167
GeneSwitch system, for EPO gene transfer, S1:50-53
Gene therapy, ligand-regulated erythropoietin gene transfer for, S1:50-53

Genetic polymorphisms
diabetic nephropathy and, 1185-1190
diabetic nephropathy progression and, S1:182-185
elevated homocysteine plasma levels and, 956-964
hemodialysis mortality risk and, 965-974
macroangiopathy in diabetic nephropathy and, 9-17
MTHFR, total homocysteine plasma levels in dialysis patients and, 77-84
renal function and, 1158-1168
renal transplantation and, 1115-1118
secondary hyperparathyroidism in uremia and, S1:143-146
Gene transcription, in kidney diseases, 1026-1037
Genotype
of adenine phosphoribosyltransferase deficiency in Iceland, 473-480
of Chinese patient with primary hyperoxaluria type 2, 1307-1310
GFR. *See* Glomerular filtration rate
Ghost albumin, excretion, in diabetic rats, 114-152
Gitelman's syndrome, progression to end-stage renal disease, 165-168
Glomerular basement membrane, in carriers of X-linked and autosomal recessive Alport's syndrome, 1217-1228
Glomerular filtration rate (GFR)
in anemia of chronic renal failure, 803-812
in diabetes mellitus, cystatin C as marker for, 310-316
in hypertensive black Americans, 744-753
rate at initiation of dialysis therapy and, 813-823
in space flights, 675-678
Glomerulonephritis
with bone marrow deposits with IgM kappa monoclonal gammopathy and hypocomplementemia, 395-399
DNA topoisomerases in, 1026-1037
focal segmental, prediction of treatment response, 406-407
hepatitis C-related, in renal transplant recipients, 919-934
in leprosy, 26-30
membranoproliferative, interferon-α with ribavirin for, 6:E35
mesangial IgA2 deposits and lectin pathway-mediated complement activation in, 1082-1088
noninflammatory, treatment of, 406-407
progression, prediction of, 728-735
tubulointerstitial fibrosis, tubular phenotypic change in, 761-769
Glomerulopathy
collagenofibrotic, 4:E15
collapsing, 5:E24
Glomerulosclerosis
diabetic, glycoxidation-modified macrophages and lipid peroxidation products in, 1016-1025
in experimental hypertension
calcium channel blocker effects on, 1292-1297
osteopontin expression and macrophage infiltration in, 153-164
focal segmental
DNA topoisomerases in, 1026-1037
long-term cyclosporine treatment for children, 754-760
Glucocorticoids, muscle loss in kidney disease and, 1337-1342
Glycoaldehyde, in ethylene glycol-mediated tubular injury, 339-348
Glycolate, in ethylene glycol-mediated tubular injury, 339-348
Glycooxylate, in ethylene glycol-mediated tubular injury, 339-348
Glycoprotein IIIa $PI^{A1/A2}$ polymorphism, diabetic nephropathy and, 1185-1190
Glycoxidation products, in diabetic nephropathy progression, 1016-1025
Glyoxylate reductase/hydroxypyruvate reductase gene mutation, in Chinese patient with primary hyperoxaluria type 2, 1307-1310
Goodpasture's syndrome
in solitary kidney, 896-900
T-cell-specific therapy for, 1321-1328
Graft. *See* Vascular access
Granulomatous renal disease, with common variable immunodeficiency, 2:E7
Growth factors, renal disease progression and, 652-657
Guanidinosuccinic acid, prostaglandin metabolism and platelet aggregation in chronic renal failure and, S1:111-114

Hansen's disease, renal lesions in, 26-30
HDL. *See* High-density lipoprotein
Head-down bed rest, as microgravity simulation model, 668-674
Heart failure, renal dopaminergic activity in, 502-509
Helicobacter pylori infection, stool antigen assay screening for assessing eradication therapy, 98-103
Hematocrit
cardiovascular complications in ESRD and, 803-812
recombinant erythropoietin response, gender, 518-522
Hematuria
in Alport's syndrome, 1217-1228
iron deposition in renal biopsy specimens from kidney disease and, 1038-1044
Hemodiafiltration therapy
identification of genomic damage to lymphocytes in, 296-301
optimally programmed, S1:220-223
outcomes based on Japanese dialysis patient registry, S1:212-216
Hemodialysis
hypertension, lisinopril for, 1245-1250
Hemodialysis (HD)
access placement with preoperative noninvasive vascular mapping, 560-564
for acute renal failure after wasp stings, 6:E33
anemia of chronic renal failure, erythropoeitin therapy, AcSDKP levels and, 510-517
antibody response after diphtheria and tetanus vaccination, 1264-1270
arteriovenous access use, timing of nephrologist referral and, 494-501
arteriovenous graft survival, angiotensin-converting enzyme inhibitors and, 1240-1244
body fat mass changes, in diabetics *vs.* nondiabetics, S1:208-211

calcitriol-resistant secondary hyperparathyroidism, paricalcitol for, S5:45-50
cardiac death, erythropoietin effect on, S1:20-25
central venous dialysis catheters, atrial thrombosis and, 631-639
chronic
cisapride effects on QT interval and dispersion in, 1284-1281
coronary artery calcification progression and dyslipidemia in, 64-69
identification of genomic damage to lymphocytes in, 296-301
intact *vs.* whole parathyroid assay, S1:172-174
pediatric, Tesio catheter usage for, 553-559
for chronic renal failure
autonomic dysfunction in, S1:118-121
cerebral oxygen metabolism in, S1:129-133
platelet aggregation and prostaglandin metabolism in, S1:111-114
complement activation suppression by cellulose dialysis membrane, 384-389
complications
catheter fracture, 858-861, 1311-1315
infected arteriovenous graft, 975-978
daily
blood pressure control and LVM reduction in hypertensive patients, 371-376
efficacy of, 225-239
for diabetes mellitus, bone metabolism biochemical markers and, S1:139-142
duration, adequacy of dialysis and, 813-823
elevated homocysteine levels, gene polymorphisms and, 956-964
erythropoietin therapy optimization, 109-117
frequent, efficacy of, 225-239
hepatitis C virus screening strategies for, 91-97, 186-188
homocysteine levels, *MTHFR* gene polymorphisms and, 77-84
in hypothermia management, 2:E8
K/DOQI guidelines, for dietary protein intake, S1:68-73
maintenance
carnitine metabolism in, S1:63-67
morbidity/mortality, malnutrition-inflammation score and, 1251-1263
simplified citrate anticoagulation for, 979-987
modifications for intradialytic hypotension reduction, S4: 18-25
mononuclear cells, Th2 phenotype and, 286-295
mortality risk, 85-90
prediction, low serum parathyroid hormone and, 1351-1357
vitamin D receptor gene polymorphisms and, 965-974
oxidative stress and inflammation in, 1408-1413
prescription and monitoring, artificial intelligence for, 1277-1283
protective effect of CETP in, 70-76
quality of life and, 443-464
recombinant erythropoietin response, 518-522
residual renal function in, 85-90
responsiveness to recombinant erythropoietin, gender and, 518-522
restless legs syndrome in, gabapentin for, 104-108
stool antigen assay screening for *H. pylori* infection eradication therapy assessment, 98-103
strategies for interdialytic hypotension prevention, S4: 1-10
survival prediction
efficacy of, 1318-1320
with forearm graft, 853-857
serum prealbumin and, 1358-1364
thiamine deficiency and unexplained encephalopathy in, 941-947
Hemodialysis catheters. *See* Catheters, dialysis
Hemodialysis membranes. *See* Dialysis membranes
Hemodynamics
in intradialytic hypotension, S4:11-17
in microgravity simulation, 668-674
Hemoglobin
darbepoetin alfa effects on, 1390-1397
outcome from EPO therapy for hemodialysis, optimizing, 109-117
Hemolytic uremic syndrome, non-O157:H7 *Escherichia coli* caused by urinary tract infection, 4:E22
Hemoperitoneum
in CAPD causing hepatocarcinoma treated with percutaneous embolization, 3:E11
Heparin, regulation of renal proximal tubular epithelial cell fibroblast growth factor-2 generation, 597-609
Hepatic failure, with interstitial nephritis and systemic eosinophilia after minocycline treatment, 6:E36
Hepatitis, fulminant, infantile, nephromegaly and elevated HGF/TGFβ_1 in, 279-285
Hepatitis B virus reactivation, in transplant recipients, lamivudine for, 1074-1081
Hepatitis C virus
cryoglobulinemic membranoproliferative glomerulonephritis, interferon-α with ribavirin for, 6:E35
infection
in chronic renal failure, reduced aminotransferase activity and, 1009-1015
renal transplantation and, 919-934
screening strategies for hemodialysis patients, 91-97, 186-188
Hepatocarcinoma, caused by hemoperitoneum in CAPD, 3:E11
Hepatocyte growth factor
inhibition apoptosis after ischemic renal injury in rats, 274-278
ratio to TGFβ_1 in infants with fulminant hepatitis or biliary atresia, 279-285
Herbal medicine, interaction with cyclosporine after renal transplantation, 1105-1107
Heroin, end-stage renal disease risk and, 49-56
High-density lipoprotein (HDL)
elevated, protective effect of CETP in hemodialysis, 70-76
postsynthetic modification of VLDL in Heymann's nephritis, 1385-1389
in uremia, impact on cardiovascular disease, S1:14-19
High-flux hemodialysis, simplified citrate anticoagulation for, 979-987

Homocysteine, plasma
in chronic renal failure, 537-546, S1:85-90
in dialysis patients, *MTHFR* gene polymorphisms and, 77-84
elevated. *See* Hyperhomocysteinemia
metabolic consequences of, S1:85-90
progression of diabetic nephropathy and, 1376-1380
Hospitalization, frequent hemodialysis and, 225-239
Hume method for men, 917(erratum)
Hume-Weyer formula for females, by BIA formula, 917(erratum)
HUS. *See* Hemolytic uremic syndrome
Hyaluronan in uremia, accelerated mononuclear adhesion and, S1:54-57
Hydraulic permeability, for removal of middle molecule uremic toxins, S1:217-219
Hypercalcemia
control, to minimized bone disease in renal failure, 1430-1436
from oral *vs.* intravenous vitamin D therapy, S5:41-44
paricalcitol dosing and, S5:57-63
from paricalcitol *vs.* calcitriol, S5:51-56
vitamin D analogues and, S5:3-19, S5:34-40
Hyperhomocysteinemia
endothelial dysfunction and, S1:95-99
gene polymorphisms and, 956-964
metabolic consequences of, S1:85-90
in renal transplant recipient, S6:36-43
treatment, in end-stage renal disease, S1:91-94
Hypericum perforatum, interaction with cyclosporine after renal transplantation, 1105-1107
Hyperlipidemia
in renal transplant recipient, S6:10-24, 36-43
treatment, renoprotection in nondiabetic chronic renal failure and, 1365-1371
Hyperparathyroidism
cardiovascular disease in end-stage renal disease and, S1:38-46
secondary
in chronic renal failure, S5:20-33
genetic aspects of, S1:143-146
maxacalcitol for, S1:147-151
paricalcitol dosing by body weight or severity of, S5:57-63
paricalcitol *vs.* calcitriol for, S5:51-56
vitamin D analogues for, S5:34-40
strategies for minimizing, 1430-1436
total parathyroidectomy with forearm autograft for, S1:168-171
vitamin D analogues for, S5:3-19
vitamin D gene receptor gene polymorphisms, hemodialysis survival and, 965-974
Hyperphosphatemia
from oral *vs.* intravenous vitamin D therapy, S5:41-44
paricalcitol dosing and, S5:57-63
from paricalcitol *vs.* calcitriol, S5:51-56
vascular calcification and, S1:34-37
vitamin D analogues and, 1430-1436, S5:34-40
Hypersensitivity reaction, acute tubulointerstitial nephritis after wasp stings, 6:E33
Hypertension
in ADPKD, exacerbation by chronic caffeine consumption, 1089-1095
in African Americans. *See* African Americans, with hypertension-related ESRD
cardiovascular disease in end-stage renal disease and, S1:38-46
cardiovascular mortality in renal disease and, S1:8-13
in chronic renal failure, 537-546
cocaine-induced, end-stage renal disease and, 523-528
control, renoprotection in nondiabetic chronic renal failure and, 1365-1371
with end-stage renal disease
cocaine and, 523-528
mitochondrial DNA mutations in, 529-536
experimental, calcium channel blocker comparison in, 1292-1297
genetic factors in, 1158-1168
with glomerulosclerosis, osteopontin expression and macrophage infiltration in, 153-164
hemodialysis-induced, lisinopril for, 1245-1250
with kidney disorder, prognosis for, 1334-1336
management and LVM reduction with short daily hemodialysis, 371-376
with nephrosclerosis, family history, dialytic survival and, 547-552
nitric oxide metabolism in chronic renal failure and, S1:74-79
pregnancy-induced, progesterone and, 893-895
in radiation-induced renal artery stenosis, 302-309
recombinant human erythropoietin-induced, S1:20-25
in renal transplant recipients, S6:10-24, 36-43
selective cyclooxygenase-2 inhibitors for, 1145-1157
Hypoalbuminemia, cardiovascular disease in end-stage renal disease and, S1:38-46
Hypocomplementemia, immunotactoid glomerulopathy with massive bone marrow deposits in, 395-399
Hypokalemic metabolic alkalosis, from cough medicine abuse, 390-394
Hypotension
AN-69 membrane hypersensitivity reactions and, 173-178
cardiovascular disease in end-stage renal disease and, S1:38-46
intradialytic. *See* Intradialytic hypotension
Hypothermia management, hemodialysis in, 2:E8

Icodextrin, for nighttime CAPD *vs.* glucose solution, 118-126
Imidazolone, localization in peritoneum of CAPD patients, S1:107-110
Immune system
effects of paricalcitol on, 792-802
response, to diphtheria and tetanus vaccination in hemodialysis patients, 1264-1270
Immunizations, for renal transplant recipients, S6:10-24
Immunoglobulin A nephropathy
enalapril and losartan for, 18-25
impact of tonsillectomy and steroid pulse therapy on remission, 736-743
iron deposition in renal biopsy specimens, 1038-1044

mesangial IgA2 deposits and lectin pathway-mediated complement activation in, 1082-1088
progression, prediction of, 728-735, 881-883
recurrent in renal transplant allografts, 588-596
renin angiotensin system inhibitors and, 182-185
steroid therapy and urinary transforming growth factor-β1 in, 1191-1198
Immunoglobulin G, serum levels for *Helicobacter pylori* infection screening, 98-103
Immunosuppression. *See also specific immunosuppressive agents*
calcineurin-free, S2:16-21
for diffuse proliferative lupus glomerulonephritis, 256-264
evolution of, S6:2-9
interaction with St. John's wort interaction, 1105-1107
for renal transplant recipients
African American, S2:11-15
diabetic with pulmonary mucormycosis, 6:E37
discontinuing in children, 901-915
evolution of, S6:2-9
long-term management, S6:51-57
maintenance therapy, S6:25-35
survival and, S6:44-50
Immunotactoid glomerulopathy, with bone marrow deposits in monoclonal gammopathy and hypocomplementemia, 395-399
Impotence, in uremic dialysis patients, S1:115-117
Income, weight gain in renal transplant recipients and, 349-353
Indinavir nephropathy, risk factors, 4:E23
Infantile biliary atresia, nephromegaly and elevated HGF/TGFβ_1 in, 279-285
Infection. *See also specific infections*
of arteriovenous graft, clinical consequences of, 975-978
in renal transplant recipients, management of, S6:10-24
Inflammation
in maintenance dialysis, clinical outcome and, 1343-1350
morbidity/mortality in maintenance hemodialysis and, 1251-1263
and oxidative stress in hemodialysis patients, 1408-1413
Inflammatory bowel disease, acute renal failure in, 205-209
Insulin
portal, kidney-pancreas transplantation outcome and, 132-143
resistance
cardiovascular mortality in renal disease and, S1:8-13
renal disease progression and, 1372-1375
secretion, in chronic renal failure, S1:58-62
α_v-Integrin, in pathogenesis of diabetic and aging nephropathy, 1298-1306
Intensive care unit, nephrologist role in, 426-429
Interferon
for cryoglobulinemia membranoproliferative glomerulonephritis, 6:E35
release in uremia, Th2 phenotype and, 286-295
Interleukin-4, release in uremia, Th2 phenotype and, 286-295
Interleukin-6, induced by binding/processing of calcium oxalate crystals in cultured macrophages, 331-338
Intermediate-density lipoproteins, in end-stage renal disease, S1:30-33
Internal filtration, for removal of middle molecule uremic toxins, S1:217-219
Interstitial nephritis
allergic, after wasp stings, 6:E33
in Crohn's disease, 205-209
with hepatic failure and systemic eosinophilia after minocycline treatment, 6:E36
post-transplant polyomavirus-associated, molecular genotyping of, 354-365
ranitidine-induced in cadaveric renal allograft, 169-172
Interstitial pressure, in microgravity simulation, 668-674
Intima-media thickness
genetic factors in, 1158-1168
renal disease progression in type 2 diabetes and, S1:186-190
Intracranial aneurysms, ruptured, family clustering in autosomal dominant polycystic kidney disease, 770-776
Intradialytic hypotension
clinical case-based approach, S4:37-47
management of, S4:1-10
pathophysiology of, S4:1-10, 11-17
pharmacologic treatment options, S4:26-36
reduction, modification of dialysis prescription for, S4:18-25
Intraperitoneal therapy, cefepime *vs.* vancomycin plus netilmicin, for CAPD-associated peritonitis, 127-131
Intravascular volume, during microgravity, 679-683
Ionic dialysance, in vivo urea clearance during hemodialysis and, 565-574
Irbesartan, *vs.* amlodipine for type 2 diabetic nephropathy, S1:191-194
Iron-deficiency anemia, transferrinuria and, 1-8
Iron deposition, in renal biopsy specimens from kidney disease, 1038-1044
Iron sucrose, intravenous, safe dosing of, 988-991
Iron therapy
increased dosage, ferritin outcome and, 109-117
intravenous
recombinant erythropoietin response, 518-522
safe dosing of, 988-991
Ischemic-reperfusion injury, protection, systemic adenosine for, 610-618

Janus kinase/signal transducers and activators of transcription, AGE-induced cell-cycle dependent cellular proliferation and, 1096-1104
Japanese dialysis patient registry, hemodiafiltration outcomes, S1:212-216
JC polyomavirus, molecular genotyping in human polyomavirus-associated interstitial nephritis after renal transplantation, 354-365

Kaposi's sarcoma, allograft dysfunction and, 658-663
Karyomegalic nephropathy, 3:E9
Kidney
biopsy specimens, iron deposition from kidney disease, 1038-1044
dopamine synthesis, in heart failure, 502-509
function
ACE gene polymorphism, α-adducin gene and aldosterone synthase gene, 1158-1168

advanced glycation end products and, S1:100-106
after long-term nephrotic range proteinuria, 1329-1333
during cyclosporine withdrawal, sirolimus effect on, S2:3-10
residual, in hemodialysis, 85-90
selective cyclooxygenase-2 inhibitors and, 1145-1157
in space, 664-667
hemodynamics in space flights, 675-678
lesions, in leprosy, 26-30
living donation, ethical issues in, 189-195
perfusion, in microgravity simulation, 668-674
transplantation. *See* Renal transplantation
Kidney Disease Outcomes Quality Initiative, dietary protein intake guidelines, S1:68-73
Kidney-pancreas transplantation
outcome, portal insulin and, 132-143
with portal-enteric *vs.* systemic-bladder drainage, long-term outcomes of, 132-143
Kidney stones. *See* Nephrolithiasis
Kimmelstiel-Wilson nodules, in diabetic nephropathy progression, 1016-1025
Kt/V. *See* Urea filtration rate/volume

Lactate buffer, for peritoneal dialysis fluid, *vs.* bicarbonate buffer, 867-875
Lamivudine, for treatment of HBV reactivation and fulminant hepatitis failure in transplant recipients, 1074-1081
LDL. *See* Low-density lipoprotein
Lecithin-cholesterol acyltransferase deficiency, 1:E1
Left ventricular hypertrophy
in adult polycystic kidney disease, 1208-1216
erythropoietin effect on, S1:20-25
in hypertensive patients on short daily hemodialysis, 371-376
Lenticonus, in Alport's syndrome, 1217-1228
Leprosy, renal lesions in, 26-30
Leukocyte common antigen, in diabetic nephropathy progression, 1016-1025
Ligand-regulated erythropoietin gene transfer, construction of, S1:50-53
Light chain cast nephropathy, in Crohn's disease, 205-209
Linear regression analysis, in predicting IgA nephropathy progression, 728-735
Linezolid, for vancomycin-resistant enterococcal peritonitis, 4:E20
Lipid peroxidation products, in diabetic nephropathy progression, 1016-1025
Lipoprotein lipase, chylomicron binding in Heymann's nephritis, high-density lipoprotein and, 1385-1389
Lipoproteins. *See also specific lipoproteins*
atherogenic, in end-stage renal disease, S1:30-33
Lp(a), renal handling in rats, 619-630
metabolism in uremia, impact on cardiovascular disease, S1:14-19
Lisinopril, for hemodialysis hypertension, 1245-1250
Liver disease
hepatitis C-related, renal transplantation and, 919-934
in renal transplant recipients, fulminant hepatic failure, lamivudine for, 1074-1081
Living organ donation, ethical issues in, 189-195
Losartan
with enalapril, antiproteinuric effect in IgA nephropathy, 18-25
optimal antiproteinuric dose in nondiabetic patients with nephrotic range proteinuria, 1381-1384
Low-density lipoprotein (LDL)
in chronic renal failure, 537-546
in end-stage renal disease, S1:30-33
oxidation in uremia, impact on cardiovascular disease, S1:14-19
Lupus nephritis, DNA topoisomerases in, 1026-1037

Macroangiopathy, in diabetic nephropathy, gene polymorphisms and, 9-17
Macrophage inflammatory protein-1α, in crescentic glomerulonephritis, 1169-1177
Macrophages
glycoxidation-modified, in diabetic nephropathy progression, 1016-1025
induced cytokine production in, 331-338
infiltration in experimental glomerulosclerosis, osteopontin and, 153-164
Macrophage scavenger receptor class A, in diabetic nephropathy progression, 1016-1025
Magnesium, in dialysate, intradialytic hypotension reduction and, S4:18-25
Majocchi's granuloma, with posttransplant lymphoproliferative disease in renal transplant recipient, 6:E38
Malnutrition
cardiovascular disease in end-stage renal disease and, S1:38-46
in maintenance dialysis, clinical outcome and, 1343-1350
morbidity/mortality in maintenance hemodialysis and, 1251-1263
thiamine deficiency and unexplained encephalopathy in dialysis, 941-947
Malnutrition inflammation complex syndrome, in maintenance dialysis, clinical outcome and, 1343-1350
Malonyldialdehyde, prostaglandin metabolism in chronic renal failure and, S1:111-114
Mannose-binding lectin-associated serine protease-1 (MASP-1), in IgA glomerulonephritis, 1082-1088
Marital dissatisfaction, in end-stage renal disease, 839-846
Mass transfer area coefficient (MTAC), increases with high-flux dialyzers, 575-579
Maude database, hemodialysis catheter fracture causing pulmonary artery embolization, 1311-1315
Maxacalcitol
for secondary hyperparathyroidism in uremia, S1:147-151
therapeutic uses of, S5:3-19
Medical device malfunction, causing pulmonary artery embolization, 1311-1315
Medical ethics. *See* Ethical issues
Medicare expenditures, on end-stage renal disease, geographic variation in, 824-831
Megalin, mediation of proximal tubule albumin reabsorption, 196-204
Membranoproliferative glomerulonephritis, HCV-associated cryoglobulinemic, interferon-α with ribavirin for, 6:E35

Membranous glomerulonephritis, DNA topoisomerases in, 1026-1037
Membranous nephropathy
  treatment controversy, 406-407
  urinary IgG and α_1-microglobulin in, 240-248
Men1 tumor-suppressor gene, in tumorigenesis, S1:165-167
Mesangial capillary glomerulonephritis, DNA topoisomerases in, 1026-1037
Mesangial deposits, of IgA2 in IgA glomerulonephritis, 1082-1088
Mesangial proliferative glomerulonephritis, DNA topoisomerases in, 1026-1037
Mesothelial cells, effect of peritoneal dialysis fluid buffers on, 867-875
Metabolic acidosis
  activation of muscle loss in kidney disease, 1337-1342
  muscle protein synthesis and albumin synthesis in, 1199-1207
  sodium bicarbonate for, 703-727
Metabolic alkalosis, hypokalemic, cough mixture-induced, 390-394
Methionine synthase gene polymorphisms, elevated homocysteine and, 956-964
5,10-Methylenetetrahydrofolate reductase, elevated homocysteine and, 956-964
5,10-Methylenetetrahydrofolate reductase *(MTHFR)*, gene polymorphisms, homocysteine in dialysis patients and, 77-84
Methylguanidine, prostaglandin metabolism and platelet aggregation in chronic renal failure and, S1:111-114
Mibefradil, *vs.* L-type calcium channel blocker in experimental hypertension, 1292-1297
Microalbuminemia, cardiovascular mortality in renal failure and, S1:8-13
Microalbuminuria
  kidney disease progression in diabetes and hypertension, 1372-1375
  in poststreptococcal acute glomerulonephritis follow-up, 249-255
β_2-Microglobulin
  absorption therapy outcome, S1:212-216
  as marker for renal impairment in diabetes mellitus, 310-316
  removal by optimally programmed hemodiafiltration, S1:220-223
Microgravity
  body mass changes, energy and protein metabolism in, 691-695
  renal and sympathoadrenal responses in, 679-683
  reversed hypothesis and, 696-698
  simulation models, validity of, 668-674
  water and sodium balance and, 684-690
Midodrine
  in case-based approach for intradialytic hypotension, S4:37-47
  for intradialytic hypotension, S4:1-10, 26-36
Mineralocorticoid receptor, activation by progesterone, 893-895
Minimal change disease, DNA topoisomerases in, 1026-1037
Minocycline, hepatic failure, interstitial nephritis and systemic eosinophilia after, 6:E36
Mitochondrial DNA mutations, in black Americans with hypertension-associated ESRD, 529-536
Mitogen-activated protein kinase, in crescentic glomerulonephritis, 1169-1177
Mitral valve
  prolapse, in polycystic kidney disease type 1, 1208-1216
  regurgitation, in polycystic kidney disease type 1, 1208-1216
Mönckeberg's medial sclerosis, in end-stage renal disease, inorganic phosphate and, S1:S47-49
Monensin ingestion, acute renal failure after, 1108-1112
Monoclonal gammopathy, immunotactoid glomerulopathy with massive bone marrow deposits in, 395-399
Monocyte chemoattractant protein-1, in crescentic glomerulonephritis, 1169-1177
Monocytes, cytokine release in uremia, Th2 phenotype and, 286-295
Mononuclear cell adhesion, in uremia, soluable Fas and hyaluronan effects on, S1:54-57
Morbidity
  in maintenance dialysis, nutrition and inflammation effects on, 1343-1350
  in maintenance hemodialysis, malnutrition-inflammation score and, 1251-1263
Mortality
  after revascularization in ESRD, 57-63
  cardiovascular, risk factors in end-stage renal disease, S1:4-7
  in diabetic nephropathy patients on hemodialysis, S1:195-199
  frequent hemodialysis and, 225-239
  in maintenance dialysis, nutrition and inflammation effects on, 1343-1350
  in maintenance hemodialysis, malnutrition-inflammation score and, 1251-1263
  prediction in dialysis, low serum parathyroid hormone and, 1351-1357
  risk, in hemodialysis, 85-90
  risk in hemodialysis, vitamin D receptor gene polymorphisms and, 965-974
Mouse
  ethylene glycol-mediated tubular injury, 339-348
  macrophages, cytokine production induced by binding and processing of calcium oxalate crystals, 331-338
MTHFR gene polymorphisms, total homocysteine plasma levels in dialysis patients and, 77-84
Mucormycosis, in diabetic renal allograft recipient, combined medical surgical therapy for, 6:E37
Multiple organ dysfunction, with disseminated tuberculosis-associated hemophagocytic syndrome, 4:E19
Multiple regression analysis, in predicting IgA nephropathy progression, 728-735
Muscle loss, in kidney disease, activation of mechanisms in, 1337-1342
Muscle protein synthesis, decreased, in metabolic acidosis, 1199-1207
Mushroom poisoning, rhabdomyolysis from, 4:E17
M694V mutation, in familial Mediterranean fever with amyloidosis, 6:E34
Mycophenolate mofetil
  adjuvant, for maintenance immunosuppression, S6:25-35

immunosuppression, S6:2-9
for renal transplant immunosuppression, S2:16-21
Myelofibrosis, in acute tumor lysis syndrome with secondary acute renal failure, 4:E21
Myocardial injury, after monensin ingestion, 1108-1112

N-Acetyl-βD-glucosaminadase, urinary, iron deposition in renal biopsy specimens from kidney disease and, 1038-1044
N-Acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), in chronic renal failure with erythropoeitin therapy, 510-517, 649-651
Na^+-H^+ exchange, in diabetic nephropathy, 465-472
Natriuresis
ground-based simulations, revised hypothesis from, 696-698
during microgravity, 679-683, 684-690
in space flights, 675-678
Natriuretic peptides
during microgravity, 684-690
in microgravity simulation, 668-674
Nephrocalcinosis, in preterm neonates, 1229-1234
Nephrolithiasis
in adenine phosphoribosyltransferase deficiency in Iceland, 473-480
macrophage cytokine production induced by calcium oxalate binding and processing, 331-338
Nephrologist
optimizing relationship with transplant center, S6:51-57
referral
delayed, determinants of, 1178-1184
duration of arteriovenous access use and, 494-501
role in intensive care unit, 426-429
Nephrology
historical aspects, 179-181
time line, 1:xvii
Nephromegaly, in infants with fulminant hepatitis or biliary atresia, 279-285
Nephropathy
amyloid, in familial Mediterranean fever, 6:E34
aristolochic acid, in Chinese patient, 5:E26
diabetic. *See* Diabetic nephropathy
IgA. *See* Immunoglobulin A nephropathy
karyomegalic, 3:E9
light chain cast, in Crohn's disease, 205-209
obstructive, connective tissue growth factor in, S1:134-138
polyomavirus BK
interstitial nephritis, molecular genotyping of, 354-365
in renal transplant recipient, 3:E13
Nephrosclerosis
benign, iron deposition in renal biopsy specimens, 1038-1044
hypertensive, family history, dialytic survival and, 547-552
in leprosy, 26-30
Nephrotic syndrome. *See also* Glomerulonephritis
aquaporin expression in proximal tubule cells after protein challenge and, 317-330
in children, long-term treatment with cyclosporine for, 754-760
chylomicron binding, high-density lipoprotein and, 1385-1389
in elderly female, 437-440
erythropoietin metabolism in, 1-8
in familial Mediterranean fever with amyloidosis, 6:E34
minimal change disease, DNA topoisomerases in, 1026-1037
radiation-induced, 302-309
transferrin metabolism in, 1-8
Netilmicin, with vancomycin *vs.* cefepime, for CAPD-associated peritonitis, 127-131
Neural networks, for prescription/monitoring of hemodialysis, 1277-1283
Neurotransmitters, central nervous system dysfunction in chronic renal failure and, S1:122-128
Nitric oxide
in intradialytic hypotension, S4:11-17
metabolism, in chronic renal failure, S1:74-79
Nitric oxide synthase, in chronic renal failure, S1:74-79
Nitric oxide synthase inhibitors, for chronic renal failure, S1:74-79
Nitrogen balance, in metabolic acidosis, 1199-1207
Nocturnal hemodialysis, efficacy of, 225-239
Nonreferral, to dialysis, 36-41
Nonsteroidal anti-inflammatory drugs, gastrointestinal effects, *vs.* selective cyclooxygenase-2 inhibitors, 1145-1157
Norepinephrine, during microgravity, 679-683
Novel erythropoiesis stimulating protein, for anemia of chronic renal failure, 1390-1397
Nutrition. *See also* Malnutrition
assessment, morbidity/mortality in maintenance hemodialysis and, 1251-1263
dietary protein intake, K/DOQI guidelines, S1:68-73
kidney disease prognosis and, 1334-1336
parathyroid hormone and mortality prediction in dialysis, 1351-1357
risk prediction, serum prealbumin and, 1358-1364
status
of diabetic *vs.* nondiabetic HD patients, body fat mass changes and, S1:208-211
in maintenance dialysis, clinical outcome and, 1343-1350
support, dialysis outcome and, 1343-1350

Obesity, in renal transplant recipients, 349-353
Obstructive nephropathy, connective tissue growth factor in, S1:134-138
Opiates, end-stage renal disease risk and, 49-56
Opti-Flow catheter, fracture, causing pulmonary artery embolization, 1311-1315
Osteocalcin
AGEs in adynamic bone disease of diabetic nephropathy and, S1:161-164
in hemodialyzed diabetic patients, S1:139-142
Osteoclast activation
in dialysis-related amyloid osteopathy, S1:156-160
in uremia, skeletal resistance to parathyroid hormone and, S1:152-155
Osteoclastogenesis
in dialysis-related amyloid osteopathy, S1:156-160

in uremia, skeletal resistance to parathyroid hormone and, S1:152-155
Osteogenesis, Mönckeberg's medial sclerosis in end-stage renal disease and, S1:S47-49
Osteopontin, glomerular expression in glomerulosclerosis of DOCA-hypertensive rats, 153-164
Osteoporosis, vitamin D analogues for, S5:3-19
Osteoprotegerin, before and after renal transplantation, S1:175-177
22-Oxacalcitriol. *See* Maxacalcitol
Oxalate nephropathy, induced by star fruit, 876-880
Oxidative stress
activation of protein kinase C in diabetic rats and, S1:204-207
causing AGEs in progressive renal disease, S1:100-106
in chronic renal failure, nitric oxide metabolism and, S1:74-79
and inflammation in hemodialysis patients, 1408-1413
in progression of diabetic nephropathy, 785-791
Oxylate, in ethylene glycol-mediated tubular injury, 339-348

Palliative care, discontinuing immunosuppression in children with renal transplants, 901-915
Pancreas transplantation, with kidney transplantation. *See* Kidney-pancreas transplantation
Pancreatic islet metabolism, insulin secretion in chronic renal failure and, S1:58-62
Panendoscopy, for *Helicobacter pylori* infection screening, 98-103
Parathyroid adenoma, 11q allelic loss in, S1:165-167
Parathyroidectomy, with forearm autograft for hyperparathyroidism, S1:168-171
Parathyroid hormone (PTH). *See also* Hyperparathyroidism
AGEs in adynamic bone disease of diabetic nephropathy and, S1:161-164
assay, intact *vs.* whole for long-term dialysis, S1:172-174
insulin secretion in chronic renal failure and, S1:58-62
as mortality predictor in dialysis, 1351-1357
neurotoxicity, in chronic renal failure, S1:122-128
paricalcitol effects on, 792-802
skeletal resistance to, S1:152-155
suppression
by maxacalcitol, S1:147-151
by oral *vs.* intravenous vitamin D analogues, S5:41-44
by paricalcitol *vs.* calcitriol, S5:51-56
Paricalcitol
in dialysis patients with calcitriol-resistant secondary hyperparathyroidism, S5:45-50
dosing by body weight or severity of hyperparathyroidism, S5:57-63
for hyperparathyroidism suppression, 1430-1436
immunomodulatory effects, 792-802
parathyroid hormone suppression, *vs.* calcitriol, S5:51-56
for secondary hyperparathyroidism, S5:34-40
Pathological grading, in predicting IgA nephropathy progression, 728-735
Patient attitudes, on cardiopulmonary resuscitation in dialysis unit, 847-852
Pauci-immune vasculitis, ANCA-negative, rapid recurrence after cadaveric renal transplantation, 1:E3
PD. *See* Peritoneal dialysis
Pediatric patients. *See* Children
Percutaneous embolization, for hepatocarcinoma caused by hemoperitoneum in CAPD, 3:E11
Percutaneous transluminal angioplasty
cardiovascular disease in end-stage renal disease and, S1:38-46
for radiation-induced renal artery stenosis, 302-309
Peripheral vascular disease revascularization, long-term outcomes of in ESRD, 57-63
Peritoneal dialysis (PD). *See also* Continuous ambulatory peritoneal dialysis
chyloperitoneum in, 3:E12
continuous, creatinine excretion in, 862-866
for diabetes mellitus, S1:200-203
elevated homocysteine levels, gene polymorphisms and, 956-964
for end-stage renal disease in Gitelman's syndrome, 165-168
fluid, lactate *vs.* bicarbonate buffered, 867-875
homocysteine levels, *MTHFR* gene polymorphisms and, 77-84
K/DOQI guidelines, for dietary protein intake, S1:68-73
mortality prediction, low serum parathyroid hormone and, 1351-1357
nonconvulsive status epilepticus in, 400-405
quality of life and, 443-464
survival prediction, serum prealbumin and, 1358-1364
thiamine deficiency and unexplained encephalopathy in, 941-947
Peritoneal equilibration test, preceding polyglucose *vs.* glucose exchange and, 118-126
Peritoneum, of CAPD patients, imidazolone in, S1:107-110
Peritonitis
CAPD-associated, cefepime *vs.* vancomycin with netilmicin for, 127-131
tuberculous, in Chinese CAPD patients, 1055-1060
pH, blood, AN-69 membrane hypersensitivity reactions and, 173-178
Pharmaceutical companies, clinical trial design and, 1113
Phenylalanine, in metabolic acidosis, 1199-1207
Phosphate
dialysate to plasma ratio during postpolyglucose exchange, 118-126
inorganic
in uremia, Mönckeberg's medial sclerosis and, S1:S47-49
vascular calcification and, S1:34-37
Phosphorus. *See also* Hyperphosphatemia
control, to minimized bone disease in renal failure, 1430-1436
intake, parathyroid hormone and mortality prediction in dialysis, 1351-1357
in secondary hyperparathyroidism with chronic renal failure, S5:20-33
Physical examination, in predicting survival of PTFE grafts, 853-857
Physicians' practice patterns, for end-stage renal disease, geographic variation in, 824-831
Plasma refilling, in intradialytic hypotension, S4:11-17

Plasma renin activity, lisinopril for hemodialysis hypertension an, 1245-1250
Plasma volume
in intradialytic hypotension, S4:11-17
in microgravity simulation, 668-674
Plasminogen activator inhibitor-1, progression of diabetic nephropathy and, 1376-1380
Platelet aggregation, and prostaglandin metabolism in chronic renal failure, S1:111-114
Platelet collagen receptor $\alpha 2\beta 1$ integrin, diabetic nephropathy and, 1185-1190
p38 mitogen-activated protein kinase, in crescentic glomerulonephritis, 1169-1177
Pollution
ANCA-positive vasculitis and, 5:E28
end-stage renal disease and, 1001-1008
Polycystic kidney disease. *See also* Autosomal dominant polycystic kidney disease
adult type 1, mitral valve prolapse and regurgitation in, 1208-1216
chronic subdural hematoma in, 2:E6
polycystin-1 characterization in, 1421-1429
type 1, mitral valve prolapse and regurgitation in, 1208-1216
Polycystin-1, biochemical characterization of, 1421-1429
Polyglandular endocrine failure, in familial Mediterranean fever with amyloidosis, 6:E39
Polyglucose icodextrin, for nighttime CAPD *vs.* glucose solution, 118-126
Polyomavirus BK nephropathy
interstitial nephritis, molecular genotyping of, 354-365
in renal transplant recipient, 3:E13
Portal-enteric drainage, for kidney-pancreas transplantation, long-term outcome and, 132-143
Positron emission tomography (PET), of cerebral oxygen metabolism in chronic renal failure, S1:129-133
Posterior urethral valve, postoperative persistent distal renal tubular acidosis, prognostic factors for, 488-493
Poststreptococcal acute glomerulonephritis, epidemic, follow-up of, 249-255
Posttransplant lymphoproliferative disease, with Majocchi's granuloma in renal transplant recipient, 6:E38
Potassium, in dialysate, intradialytic hypotension reduction and, S4:18-25
Power spectral analysis, in chronic renal failure, S1:118-121
Prealbumin, serum, in dialysis survival prediction, 1358-1364
Predialysis, quality of life in, 443-464
Prednisone, with calcineurin-free immunosuppression for renal transplant recipients, S2:16-21
Pre-eclampsia/eclampsia, 2:E4
Pregnancy
hypertension induced by, progesterone and, 893-895
maintenance immunosuppression and, S6:25-35
in renal transplant recipients, S6:10-24, 25-35
Preterm neonates, modulation of calcium oxalate monohydrate crystallization kinetics, 1229-1234
Primary care physicians, nonreferral and nonacceptance to dialysis, 36-41
Primary hyperoxaluria type 2, with novel *GRHPR* gene mutation in Chinese patient, 1307-1310
Progesterone, renin-angiotensin-aldosterone system inhibition and, 893-895
Programmed cell death. *See* Apoptosis
Progression
of Bartter's syndrome variant, 165-168
of chronic renal failure
growth factors and, 652-657
in type 2 diabetes, atherosclerosis and, S1:186-190
of diabetic nephropathy, 1376-1380
advanced glycation end products and, 785-791
advanced glycation end products in, S1:100-106
atherosclerosis and, S1:186-190
cellular mechanisms of, S1:178-181
glycoxidation-modified macrophages and lipid peroxidation products in, 1016-1025
microalbuminuria/proteinuria and, 1372-1375
proteinuria and, S1:8-13
T29C gene polymorphism and, S1:182-185
of kidney disease
advanced glycation end products in, S1:100-106
with cardiovascular disease, 1398-1407
microalbuminuria/albuminuria in, 1372-1375
reduction of proteinuria and, S1:8-13
in type 2 diabetes, atherosclerosis and, S1:186-190
prediction, in immunoglobulin A nephropathy, 728-735, 881-883
referral, early *vs.* late, economic evaluation of, 1122-1128
selective cyclooxygenase-2 inhibitors and, 1145-1157
Propionibacterium acnes, shunt nephritis in solitary kidney, 4:E17
Prostaglandin metabolism, and platelet aggregation, in chronic renal failure, S1:111-114
Proteasomes, loss of muscle mass in kidney disease and, 1337-1342
Protein. *See also* Proteinuria
damage, in chronic renal failure, S1:85-90
dietary intake
K/DOQI guidelines, S1:68-73
PTH and mortality prediction in dialysis and, 1351-1357
dietary restriction, renoprotection in nondiabetic chronic renal failure and, 1365-1371
metabolism, during space flights, 691-695
urinary biomarkers, analysis via biomolecular interaction analysis mass spectrometry, 481-487
Protein catabolic rate, of male hemodialysis patients, diabetic *vs.* nondiabetic, S1:208-211
Protein-energy malnutrition. *See* Malnutrition
Protein kinase C
activation, by oxidative stress in diabetic rats, S1:204-207
progression of diabetic nephropathy and, S1:178-181
Proteinuria
and cardiovascular disease, S1:8-13
effect on aquaporin expression in proximal tubule cells, 317-330
in experimental hypertension, calcium channel blocker effects on, 1292-1297
in IgA nephropathy, enalapril and losartan effect on, 18-25
in multiracial pediatric population, low body weight and, 1045-1054
nephrotic range

long-term, without loss of renal function, 1329-1333
in nondiabetic patients, optimal antiproteinuric losartan dose, 1381-1384
reduction, renoprotection in nondiabetic chronic renal failure and, 1365-1371
renal disease progression and, 1372-1375
Proximal tubule
albumin reabsorption and handling, 196-204
cultured human cells, aquaporins in transferrin upregulation of, 317-330
P-selectin-dependent thrombotic glomerulonephritis, effect of synthetic selectin blocker in, 265-273
Psoriasis, vitamin D analogues for, S5:3-19
PTH. *See* Parathyroid hormone
Pulmonary artery embolization, from hemodialysis catheter fracture, 1311-1315
Pulmonary embolism, central venous dialysis catheters and, 631-639
Pyridinolone, in hemodialyzed diabetic patients, S1:139-142

QT interval, in chronic hemodialysis, cisapride effects on, 1284-1281
Quality of life
in end-stage renal disease, 443-464
frequent hemodialysis and, 225-239
for renal transplant recipients, 580-587
Questionnaire, factors affecting referral decisions, 42-48

Race
dialytic survival in end-stage renal disease and, 547-552
responsiveness to recombinant erythropoietin and, 518-522
Radiation therapy, renal artery stenosis-induced by, 302-309
Radioimmunoassay, of albumin fractional clearance in diabetic rats, 144-152
Ranitidine-induced interstitial nephritis, in cadaveric renal allograft, 169-172
RANKL/OPFGL (receptor activator of nuclear factor-κB ligand/osteoprotegerin ligand), in dialysis-related amyloid osteopathy, S1:156-160
Rapidly progressive glomerulonephritis, DNA topoisomerases in, 1026-1037
Rats
acute oxalate nephropathy induced by star fruit, 876-880
acute thrombotic glomerulonephritis, synthetic selectin blocker effects on, 265-273
with ADPKD, exacerbation of hypertension by chronic caffeine consumption, 1089-1095
apoptosis after ischemic renal injury, inhibition by hepatocyte growth factor, 274-278
crescentic glomerulonephritis, p38 mitogen-activated protein kinase in, 1169-1177
with Heymann's nephritis, endothelial chylomicron binding alteration by HDL, 1385-1389
hypertensive
calcium channel blocker comparison in, 1292-1297
glomerular osteopontin expression and macrophage infiltration in, 153-164
obstructive nephropathy, connective tissue growth factor in, S1:134-138
renal handling of apolipoprotein(a) in, 619-630
streptozotocin-induced diabetic
activation of protein kinase C by oxidative stress, S1:204-207
alterations of vitronectin and α_v-integrin in, 1298-1306
immuno-unreactive albumin excretion in, 144-152
oxidative stress activation of PKC in, S1:204-207
progression of renal disease in, S1:178-181
Reactive oxygen species, nitric oxide metabolism in chronic renal failure and, S1:74-79
Receptor activator of nuclear factor-κB
in dialysis-related amyloid osteopathy, S1:156-160
osteoprotegerin levels, renal transplantation and, S1:175-177
Recombinant human erythropoietin. *See* Erythropoietin, recombinant human
Red cell
deformability, in diabetic azotemic and uremic patients, erythropoietin and, 14114-1420
hypochromicity, erythropoietin therapy for hemodialysis and, 109-117
Referral
decisions
factors affecting, 42-48
nonreferral and nonacceptance to dialysis, 36-41
duration of arteriovenous access use and, 494-501
early *vs.* late for progressive renal failure, economic evaluation of, 1122-1128
Renal artery stenosis, radiation-induced, 302-309
Renal biopsy specimens, iron deposition from kidney disease, 1038-1044
Renal failure. *See* Acute renal failure; Chronic renal failure; End-stage renal disease
Renal failure progression. *See* Progression
Renal interstitial fibrosis, heparin effect on proximal tubular epithelial cell FGF-2 and, 587-609
Renal ischemia-reperfusion injury, complement and, 430-436
Renal lesions, in leprosy, 26-30
Renal osteodystrophy
frequent hemodialysis and, 225-239
impaired PTH secretion in diabetic hemodialyzed patients and, S1:139-142
strategies for minimizing, 1430-1436
Renal plasma flow, in space flights, 675-678
Renal replacement therapy. *See specific renal replacement therapies*
for cadmium-related end-stage renal disease, 1001-1008
continuous, AN-69 membrane hypersensitivity reactions, 173-178
Renal transplantation. *See also* Renal transplant recipients
cadaveric
ranitidine-induced acute interstitial nephritis in, 169-172
rapid recurrence of ANCA-negative pauci-immune vasculitis after, 1:E3
for chronic renal failure, autonomic dysfunction in, S1:118-121
elevated homocysteine levels, gene polymorphisms and, 956-964
for end-stage renal disease, S3:117-134

failure, G200210A prothrombin gene mutation and, 1061-1064
genetic polymorphisms and, 1115-1118
graft loss, outcomes of, 31-35
hepatitis C virus infection and, 919-934
for hyperhomocysteinemia treatment in end-stage renal disease, S1:91-94
immunosuppression. *See* Immunosuppression
living donor
ethical issues in, 189-195
for primary hyperoxaluria type 2 with novel *GRHPR* gene mutation, 1307-1310
osteoprotegerin levels and, S1:175-177
pediatric, body composition after, 366-370
polyomavirus-associated interstitial nephritis, molecular genotyping of, 354-365
quality of life and, 443-464
survival
after ESRD in autosomal dominant polycystic kidney disease, 777-784
long-term, S6:44-50
Wegener's granulomatous recurrence 13 years after, 6:E32
weight gain after, 409-410
Renal transplant recipients
African-American, TOR inhibitors and other immunosuppressive regiments for, S2:11-15
cardiovascular disease in, S6:36-43
children
discontinuing immunosuppression in, 901-915
safety/efficacy of TOR inhibitors for, S2:22-28
emphysematous urinoma in, 5:E29
HBV-negative and HBC-negative, fibrosing cholestatic hepatitis in, 640-645
hepatitis B virus reactivation and fulminant hepatic failure, lamivudine for, 1074-1081
hepatitis C infection in, 919-934
life satisfaction in, 580-587
long-term care and general health management of, S6:10-24
long-term management, S6:51-57
with Majocchi's granuloma and posttransplant lymphoproliferative disease, 6:E38
polyomavirus BK nephropathy in, 3:E13
weight gain, variables in, 349-353
Renin aldosterone, during microgravity, 684-690
Renin-angiotensin-aldosterone system, progesterone inhibition of, 893-895
Renoprotection
after ischemia, systemic adenosine for, 610-618
of angiotensin II receptor blocker *vs.* calcium channel blocker for type 2 diabetic nephropathy, S1:191-194
in nondiabetic chronic renal failure, 1365-1371
optimal antiproteinuric losartan dose in nondiabetic patients with nephrotic range proteinuria, 1381-1384
Residual renal function, in hemodialysis, 85-90
Restless legs syndrome, in hemodialysis, gabapentin for, 104-108
Retransplantation, after graft loss, 31-35
Rhabdomyolysis
after monensin ingestion, 1108-1112
from mushroom poisoning, 4:E17
rHuEPO. *See* Erythropoietin, recombinant human
Ribavirin, for cryoglobulinemia membranoproliferative glomerulonephritis, 6:E35
Ruptured intracranial aneurysms, family clustering in autosomal dominant polycystic kidney disease, 770-776

Salt sensitivity, cardiovascular mortality in renal disease and, S1:8-13
Scanning electron microscopy
for analysis of spontaneous hemodialysis catheter fracture, 858-861
of calcium phosphate depositions in stenotic atriovenous fistulas, 377-383
Sclerosing peritonitis, CAPD, localization of imidazolone in peritoneum, S1:107-110
Selectin blocker, effects on acute thrombotic glomerulonephritis, 265-273
Sepsis, of diabetic nephropathy patients on hemodialysis, S1:195-199
Sertraline, for intradialytic hypotension, S4:26-36
Sex, weight gain in renal transplant recipients and, 349-353
Sex disorders, in renal transplant recipients, 580-587
Sheehan's syndrome, sodium and water disturbances in, 3:E14
Shunt nephritis, from *Propionibacterium acnes* in solitary kidney, 4:E17
Sildenafil, for erectile dysfunction in uremic dialysis patients, S1:115-117
Silica exposure, ANCA-positive vasculitis and, 5:E28
Sirolimus
for African-American transplant recipients, S2:11-15
effect on cyclosporine withdrawal, S2:3-10
maintenance, for renal transplant recipients, S6:25-35
for renal transplant immunosuppression, S2:16-21
safety/efficacy for pediatric renal transplant recipients, S2:22-28
Skin fibroblasts, human cultured, in diabetic nephropathy, 465-472, 646-648
Sleep apnea, cardiovascular disease in end-stage renal disease and, S1:38-46
Smoking cessation
for renal transplant recipients, S6:10-24
renoprotection in nondiabetic chronic renal failure and, 1365-1371
Social support, of patient and spouse, in end-stage renal disease, 839-846
Sodium
balance, during microgravity, 684-690
in dialysate
in case-based approach for intradialytic hypotension, S4:37-47
intradialytic hypotension reduction and, S4:18-25
ratio to plasma, during postpolyglucose exchange, 118-126
disturbances, in Sheehan's syndrome, 3:E14
Sodium bicarbonate, for severe acidemic states, 703-727
Sodium-dependent phosphate cotransporter, vascular calcification and, S1:34-37
Solitary kidney, Goodpasture's syndrome in, 896-900

SP-40,40, after hemodialysis with cellulose membranes, 384-389
Space flights
  body mass changes, energy and protein metabolism in, 691-695
  fluid balance and kidney function in, 664-667
  renal and sympathoadrenal responses in, 679-683
  renal hemodynamics in, 675-678
  revised hypothesis and, 696-698
  validity of microgravity simulation models, 668-674
  water and sodium balance and, 684-690
St. John's wort, interaction with cyclosporine after renal transplantation, 1105-1107
Star fruit ingestion, acute oxalate nephropathy and, 876-880
Status epilepticus, nonconvulsive, in peritoneal dialysis patient, 400-405
Steroids
  for acute allergic interstitial nephritis after wasp stings, 6:E33
  for IgA nephropathy, 1191-1198
  pulse therapy, immunoglobulin A nephropathy remission and, 736-743
Stool antigen assay, for *H. pylori* infection eradication therapy assessment, 98-103
Streptococcus zooepidemicus glomerulonephritis, follow-up of, 249-255
Streptozotocin-induced diabetes. *See* Rats, streptozotocin-induced
Stroke, end-stage renal disease incidence after, 1235-1239
Subdural hematoma, in polycystic kidney disease, 2:E6
Substance abuse
  end-stage renal disease risk and, 49-56
  hypertension-related end-stage renal disease and, 523-528
Sulfatide derivative, effects on acute thrombotic glomerulonephritis, 265-273
Sulfur amino acid metabolism, in chronic renal failure, endothelial dysfunction and, S1:95-99
Supportive care, for renal disease patients, 884-886
Surgical technique, long-term outcome for kidney-pancreas transplantation and, 132-143
Survival
  after ESRD in autosomal dominant polycystic kidney disease, 777-784
  of diabetic patients on peritoneal dialysis, S1:200-203
  long-term renal transplantation, S6:44-50
  vitamin D gene receptor gene polymorphisms in hemodialysis patients and, 965-974
Sympathetic nervous system
  activity, during microgravity, 679-683
  in intradialytic hypotension, S4:11-17
Systemic lupus erythematosus, glomerulonephritis, cyclophosphamide-containing regimens for, 256-264

Tacrolimus
  for African-American transplant recipients, S2:11-15
  maintenance, for renal transplant recipients, S6:25-35
Target, treatment. *See* Treatment targets
Target of rapamycin inhibitors (TOR)
  for African-American transplant recipients, S2:11-15
  effect on cyclosporine withdrawal, S2:3-10
  immunosuppression, S6:2-9
  safety/efficacy for pediatric renal transplant recipients, S2:22-28
Taurine, inhibition of oxidative stress activation of protein kinase C in diabetic rats, S1:204-207
T-cell-specific therapy, for autoimmune glomerulonephritis, 1321-1328
Tesio catheter, for chronic hemodialysis in children, 553-559
Tetanus vaccination, antibody response in hemodialysis patients, 1264-1270
THAM (tris-hydroxymethyl aminomethane), for severe acidemic states, 703-727
T-helper lymphocytes, Th2 phenotype in uremia, 286-295
Therapeutic targets, of vitamin D analogues, S5:3-19
Thiamine deficiency, and unexplained encephalopathy in hemodialysis and peritoneal dialysis, 941-947
Thrombin, platelet aggregation in chronic renal failure and, S1:111-114
Thrombogenicity, end-stage renal disease mortality, interdialytic hypotension and, S4:1-10
Thrombophilia, in graft failure, G200210A prothrombin gene mutation and, 1061-1064
Thrombosis, with cytomegalovirus infection in ANCA-positive vasculitis, 5:E27
Thyroid function, in chronic renal failure, S1:80-84
Thyroid hormones
  in chronic renal failure, S1:80-84
  in metabolic acidosis, 1199-1207
Tip lesion, 6:E30
Tonsillectomy, immunoglobulin A nephropathy remission and, 736-743
TOR inhibitors. *See* Target of rapamycin inhibitors
Total body water
  by BIA formula, 917(erratum)
  in hemodialysis, bioimpedance spectroscopy of, 832-838
Transdifferentiation, of tubular epithelial cells in progressive tubulointerstitial fibrosis, 761-769
Transferrin
  metabolism, in nephrotic syndrome, 1-8
  upregulation in cultured human proximal tubular cells, aquaporins and, 317-330
Transforming growth factor-β
  in diabetic patients on peritoneal dialysis, S1:200-203
  profibrotic action, role of connective tissue growth factor in, S1:134-138
  ratio to HGF in infants with fulminant hepatitis or biliary atresia, 279-285
  as target for diabetic nephropathy treatment, 887-892
  T29C polymorphism, diabetic nephropathy progression and, S1:182-185
  urinary, in IgA nephropathy, 1191-1198
Transluminal angioplasty, for radiation-induced renal artery stenosis, 302-309
Transmembrane pressure, in optimally programmed hemodiafiltration, S1:220-223
Transplant center, optimizing relationship with nephrologist, S6:51-57
Transplant rejection. *See* Allograft, rejection
Treatment targets
  clinical outcome and, 411-414

transforming growth factor-β in diabetic nephropathy, 887-892
Treatment withdrawal, discontinuing immunosuppression in children with renal transplants, 901-915
Treatment withholding, nonreferral to dialysis, 36-41
Trichophyton rubrum granuloma, with posttransplant lymphoproliferative disease in renal transplant recipient, 6:E38
Triple therapy, for *Helicobacter pylori* infection, 98-103
Tris-hydroxymethyl aminomethane (THAM), for severe acidemic states, 703-727
Tuberculosis infection, in Chinese CAPD patients, 1055-1060
Tubular necrosis, apoptosis, hepatocyte growth factor inhibition of, 274-278
Tubulointerstitial fibrosis
progressive, tubular phenotypic change in human glomerulonephritis, 761-769
role of connective tissue growth factor in profibrotic actin of TGF-β, s1:134-138
Tubulointerstitial nephritis, after wasp stings, 6:E33
Tumorigenesis, allelic loss in, S1:165-167
Tumor necrosis factor
induced by binding/processing of calcium oxalate crystals in cultured macrophages, 331-338
osteoprotegerin levels, renal transplantation and, S1:175-177
Tunneled catheter, spontaneous fracture and embolization into pulmonary artery, 1311-1315

Ubiquitin-proteasome system, loss of muscle mass in kidney disease and, 1337-1342
Ultrafiltration
capacity of peritoneal membrane in CAPD patients, 3-deoxyglucosone and, S1:107-110
for removal of middle molecule uremic toxins, S1:217-219
United States
factors affecting referral decisions, 42-48
nonreferral to dialysis, 36-41
United States Renal Data System (USRDS)
2001 annual data report, S3:7-238
co-investigators, S3:236-237
products and services, S3:238-247
staff, S3:236-237
Urea clearance, during hemodialysis, ionic dialysance and, 565-574
Urea filtration rate/volume (Kt/V)
duration of dialysis and, 813-823
increases with high-flux dialyzers, 575-579
Urea kinetics control, artificial intelligence for, 1277-1283
Urea reduction ratio (URR)
duration of dialysis and, 813-823
recombinant erythropoietin response, gender, 518-522
Uremia. *See* Chronic renal failure
Uremic toxins
effects on prostaglandin metabolism and platelet aggregation, S1:111-114
metabolic consequences in chronic renal failure, S1:85-90
middle molecule, dialysis membrane for removal of, S1:217-219
Urinoma, in renal transplant recipients, 5:E29
URR. *See* Urea reduction ratio

Vancomycin, with netilmicin *vs.* cefepime, for CAPD-associated peritonitis, 127-131
Vancomycin-resistant enterococcal peritonitis, linezolid therapy for, 4:E20
Variable flow Doppler measurement, of hemodialysis access flow *vs.* ultrasound dilution method, 935-940
Vascular access
arteriovenous graft survival, angiotensin-converting enzyme inhibitors and, 1240-1244
blood flow
rate, physical signs and, 853-857
suboptimal, optimizing by rate increase for dialysis dose, 948-955
variable Doppler *vs.* ultrasound dilution measurements, 935-940
of calcium phosphate depositions in, 377-383
graft loss outcomes, 31-35
infected arteriovenous grafts, clinical consequences of, 975-978
monitoring, variable Doppler *vs.* ultrasound dilution method, 935-940
placement with preoperative noninvasive vascular mapping, 560-564
stenosis, brushite precipitation in, 377-383
suboptimal, optimizing dialysis dose by increasing blood flow rate, 948-955
survival
ACE inhibitors and, 1240-1244
G200210A prothrombin gene mutation and, 1061-1064
Tesio catheter for chronic hemodialysis in children, 553-559
Vascular calcification
inorganic phosphate and, S1:34-37
Mönckeberg's medial sclerosis in end-stage renal disease and, S1:S47-49
Vascular disease
chronic renal failure and, 537-546
prevention, in hemodialysis, cholesteryl ester transfer protein and, 70-76
revascularization, long-term outcomes of in ESRD, 57-63
Vascular endothelial growth factor, in diabetic patients on peritoneal dialysis, S1:200-203
Vascular mapping, preoperative noninvasive for vascular access placement, 560-564
Vascular resistance, in intradialytic hypotension, S4:11-17
Vasopressin
for intradialytic hypotension, S4:26-36
during microgravity, 684-690
Verapamil, insulin secretion in chronic renal failure and, S1:58-62
Viagra, for erectile dysfunction in uremic dialysis patients, S1:115-117
Vitamin B_{12}
elevated homocysteine plasma levels and, 956-964
homocysteine levels in dialysis, *MTHFR* gene polymorphisms and, 77-84

Vitamin D analogues. *See also specific vitamin D analogues*
for calcitriol-resistant secondary hyperparathyroidism, S5:45-50
dosing by body weight or severity of hyperparathyroidism, S5:57-63
for hyperparathyroidism suppression, 1430-1436
immunomodulatory effects of, 792-802
oral *vs.* intravenous therapy for dialysis patients, S5:41-44
for secondary hyperparathyroidism, S5:20-33, 34-40
therapeutic uses of, S5:3-19
Vitamin D receptor gene polymorphisms, mortality risk in hemodialysis and, 965-974
Vitronectin, in pathogenesis of diabetic and aging nephropathy, 1298-1306
Wasp stings, acute allergic interstitial nephritis after, 6:E33
Water disturbances, in Sheehan's syndrome, 3:E14
Water immersion, as microgravity simulation model, 668-674
Watson formula for males, 917(erratum)
Wegener's granulomatous, recurrence 13 years after renal transplantation, 6:E32
Weight gain, in renal transplant recipients, 349-353, 409-410
Weightlessness, ground-based simulations, revised hypothesis from, 696-698
Withholding treatment, discontinuing immunosuppression in children with renal transplants, 901-915
Women, responsiveness to recombinant erythropoietin and, 518-522